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ABSTRACT
Forensic practitioners have long sought efficient and reliable means for identifying
those samples that are best suited for successful genetic profiling. Traditional serological
screening methodologies rely upon enzyme activity and antibody-based serological tests.
These tests can be consumptive, laborious and costly while reliance on antibody-based
serological testing can be prone to error.

Positive results resulting from non-target

biological fluids, the potential for cross-reactivity and non-specific binding events yield
merely presumptive results. This has led forensic biologists to omit serological testing, at
least in the case of sexual assault kit samples, in favor of Y-Screen assays. While these YScreen approaches achieve rapid screening of samples for the presence of a detectible male
DNA, they do not provide any serological information and therefore lack critical
investigative/biological context.
A more sensitive and accurate technology for the confirmatory identification of
biological fluids would greatly bolster the weight of serological evidence presented in court
and assist with more informed sample prioritization. A particularly promising approach
combines high-specificity protein biomarkers with a target-ion mass spectrometry.
Applying absolute quantitation of protein targets in the biomarker panel
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will enable forensic practitioners to make fuller use of serological information in their
decision making on downstream analyses in order to improve the successful analysis of
challenging sexual assault samples.
This research demonstrated the prevalence of false-positive results associated with
antibody-based serological methods, developed and validated a multiplex targeted-ion
mass spectrometry-based assay for the identification of six forensically relevant biological
fluids, demonstrated improved sensitivity and specificity of mass-spectrometry based body
fluid identification as compared to traditional techniques, developed a modified assay for
seminal fluid compatible with sexual assault kit evidence and evaluated the relationship
between quantitative levels of target seminal fluid peptides and the ability to generate YSTR profiles. These results provide the forensic and criminal justice communities with a
powerful tool to aid in the criminal investigation of violent crimes.
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CHAPTER 1: INTRODUCTION
1 Introduction

Forensic serology is the study of blood, saliva, semen and other bodily fluids in
relation to legal matters [1].

Biological fluid detection and identification provides

important contextual information to a forensic investigation. While genetic testing can
help to establish from whom DNA may have come, only serological testing can provide an
indication of the body fluid or tissue from which a DNA profile may have originated [2].
There exist myriad examples of how the unambiguous identification of biological fluids
can be critical to an investigation. Take for example the analysis of a victim’s clothing
from an alleged sexual assault. The identification of biological stains such as semen
through forensic serological techniques may render more probable the inference that a
sexual act occurred while a match between the DNA profile generated from that stain and
a suspect’s reference profile helps to establish a link between the suspect and victim. Both
pieces of information can be presented in court to corroborate allegations of sexual assault
by a given suspect. The ability to obtain the most probative value from a biological stain
in a criminal investigation, therefore, requires both the development of an interpretable
DNA profile and the identification of the biological substance from which the profile
originated.

1

1.1 Past and Current Serological Techniques

Current forensic tools for the identification of biological fluids are based on the
same fundamental methods that have been employed for much of the history of forensic
science. Namely, these are chemical reactions involving components of a body fluid;
detection of enzymatic activity (typically through colorimetric reactions) characteristic of
a body fluid; immunological binding to antigens that are characteristic of a body fluid or,
in the case of semen, direct visualization of spermatozoa by microscopy. All of these
techniques have value to forensic investigations; however, they also suffer from a variety
of substantial test-specific limitations. These tests as they apply to the identification of
blood, semen, saliva, urine, vaginal fluid and feces will be outlined below as will their
advantages and limitations.

1.1.1 Presumptive Detection of Blood

Bloodstains are commonly submitted for analysis as part of criminal investigations.
Blood as a matrix is composed of a watery, protein rich fluid called plasma and a cellular
component comprised of erythrocytes, leukocytes and thrombocytes. Erythrocytes are
responsible for the transport of oxygen throughout the body and mainly consist of the
metalloprotein hemoglobin. Given its high abundance in blood, the hemoglobin protein
has long served as the primary target for most blood detection reactions. Normal adult
hemoglobin consists of four globular polypeptide chains (2α chains and 2β chains), each
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of which is tightly associated with a non-protein heme group, an iron ion held in a
porphyrin ring.
Currently, the most common form of presumptive tests for suspected bloodstains
are chemical color reaction based assays as exemplified by the phenolphthalein or KastleMeyer test. This reaction takes advantage of the peroxidase-like activity of heme. The iron
in heme readily transitions between the ferrous and ferric state. This movement of
electrons helps catalyze a reaction with a peroxide group (most commonly in the form of
hydrogen peroxide) to create free radical species. These free radicals then react with an
indicator compound (e.g., phenolphthalin), which becomes oxidized to phenolphthalein
(Figure 1) generating a bright pink color indicative of a positive result (Figure 2) [3].
Additional chemical color tests for blood that follow the same reaction mechanism employ
tetramethylbenzidine (used commercially in the Hemastix® test), orthotolidine,
leucomalachite green and luminal. These assays, while extremely sensitive, are not
specific. Strong chemical oxidants (such as hypochlorite ions in bleach and household
cleaners or metal salts like copper and nickel salts) can directly oxidize an indicator
compound to produce a color change in the absence of heme. Additionally, there are many
plant tissues (i.e., potato, tomato, red onion, horseradish) that possess peroxidase-like
activity that will also catalyze this reaction [4]. Additionally, strong reductants, when
present, may cause false negative results [3].

3

Figure 1: Chemical reaction of underlying the phenolphthalein assay (Kastle-Meyer
reaction) for the presumptive detection of blood. Phenolphthalin (colorless) is oxidized in
the presence of hydrogen peroxide and heme to produce phenolphthalein which appears
pink.

Figure 2: Photograph of phenolphthalein assay results. The swab on the left is an example
of a negative reaction. The swab on the right provides an example of a positive reaction.

Microcrystal assays have also been historically used for bloodstain detection.
These tests apply chemicals to suspected bloodstains to form characteristic heme crystals.
In 1853, the Teichmann crystal assay was developed. In this assay, glacial acetic acid and
salts (potassium bromide, potassium chloride and potassium iodide) were used to react with
4

hematin to form characteristic brown rhomboid crystals [3]. In 1912, the Takayama
method in which heme was combined with sodium hydroxide, saturated glucose, pyridine
and water was published. This method produced characteristic feathery reddish/purple
crystals, comprised of pyridine ferroprotoporphyrin ring structures that could be readily
viewed under polarized light [1]. While more specific than the catalytic color reactions for
blood, these microcrystalline tests produced positive results with heme containing
molecules other than hemoglobin, such as bacterial catalases and peroxidases [5].
Additionally, in cases where dilute or only trace quantities of evidence are available, crystal
assays were found to lack the sensitivity required for the reliable detection of blood in many
forensic contexts.
Immunological reactions are also commercially available for blood detection.
These include Hexagon OBTI (Human Gesellschaft fur Biochemica), HemDirect
(Seratec®), ABAcard HemaTrace® (Abacus Diagnostics) and RSIDTM Blood (Independent
Forensics). The first three detect hemoglobin in blood while RSIDTM Blood targets
glycophorin A on the surface of red blood cells. Glycophorin A is a transmembrane protein
responsible for cell-cell binding interactions [6].

All four of these methods are

immunochromatographic assays. Therefore, they function in a similar manner and are
subject to similar limitations.
In an immunochromatographic assay, labeled (e.g., colloidal gold conjugated)
mobile-phase antibodies specific to a protein antigen (i.e., a biomarker) of interest are
localized to a sample well within an immunochromatographic assay cartridge. When an
5

aqueous sample extract is added, the target antigen binds with these antibodies and the
complex diffuses down a nitrocellulose membrane. Immobilized at a test site in the
membrane are additional antibodies for a second epitope on the target protein. This binds
to the antigen-antibody complex and produces a line to indicate a positive result based on
the accumulation of labeled antibodies at the test site. An internal control consisting of
immobilized anti-immunoglobulin antibodies that are specific to the antibodies contained
on the dye-labeled mobile-phase particles form the sample well is also built into the assay.
The internal control antibodies are patterned into an immobilized control line further down
the test strip (Figure 3). Test results are only considered valid when the line in the control
zone can be observed. A positive result therefore appears as at least two colored lines, one
at the test zone and one at the control zone, whereas a negative test result appears as a
single line at the control zone (Figure 4). The specificity of some of these assays for
hemoglobin and glycophorin A is such that they are capable of distinguishing between
human blood (and that of higher order primates) and the blood of other nonhuman species.
Therefore, they can be used not only for presumptive blood detection but also for
presumptive species categorization.
While sensitive, fast and easy to use, these assays can be costly and suffer from a
lack of body fluid specificity. Target protein biomarkers present at lower concentrations
in other biological fluids can also generate a positive reaction [7]. For example, the
sensitivity of the ABAcard HemaTrace® can be as low as 0.07 μg/mL of hemoglobin,
making the assay more sensitive than chemical color reactions for blood. As a result,
however, the test has been shown to produce positive results with seminal fluid stains, and
6

oral, vaginal, anal, and rectal swabs. At this level of sensitivity, it is thought that the assay
is detecting very low amounts of hemoglobin in these non-target fluids; thereby generating
false positive reactions in regard to the biological fluid being targeted [3]. Unpredictable
cross-reactivity with non-target molecules having similar conformational epitopes is also
possible as are non-specific binding events due to extremes of pH or other sample-specific
chemical compounds. Environmental contaminants also have the possibility of interfering
with antibody binding [7]. Degraded samples will not work with these assays due to loss
of conformational integrity of the target protein. Additionally, at high concentrations of
target antigen, these tests suffer from a phenomena called the high-dose hook effect,
leading to false negative reactions [8].

Figure 3: Lateral Flow Immunochromatographic Test Strip Design
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Figure 4: Immunochromatographic Assay depicting a positive (top) and negative (bottom)
reaction. (a) In the sample well the target antigen (hemoglobin or glycophorin A in the
case of blood assays) present in the sample binds to the mobile phase antibodies conjugated
to colloidal gold particles. (b) At the test zone, the colloidal gold conjugated antigenantibody complex to binds to immobilized target antigen antibodies to form a labeled
antibody antigen antibody sandwich. If the sample is positive, colloidal gold conjugated
antigen-antibody complex will start to accumulate in these sandwich formations forming a
visible colored line at the test zone. If the sample is negative, the antigen-free colloidal
gold conjugated antibodies will flow past the test zone. (c) At the control zone, the
antigen-free colloidal gold conjugated antibodies from the sample well will bind to
immobilized anti-immunoglobulin antibodies forming a visible colored line at the control
zone. (d) A positive test result has a line at both the test and control zones. A negative
test has no line at the test zone and a line at the control zone.

More historical methods of species identification also employed antigen-antibody
interactions but were based on the visualization of a precipitation reaction following
immunodiffusion. The most basic example of this approach was the ring assay in which a
sample extract, containing target antigens if positive, is layered on top of an antisera
solution without mixing. Both antigen and antibody will diffuse (double immunodiffusion)
8

toward each other. In a positive reaction, a white precipitate forms at the interface of the
two layers. Another example of a double immunodiffusion assay is the Ouchterlony assay.
This assay is performed by punching a series of wells into an agarose gel matrix. Antisera
is loaded into one well and sample extracts possibly containing target antigens are loaded
into surrounding wells. The gel is then incubated to allow for the diffusion of both antigen
and antibody through the gel matrix. When target antigens are present, a precipitate line
will form between the sample well and the well containing antisera (Figure 5). In lieu of
passive diffusion, an electric field can be applied to the gel such as during cross-over
electrophoresis. This serves to drive antigens across an agar gel resulting in enhanced
sensitivity. As with the ring and Ouchterlony assays, a positive reaction is denoted by
formation of a visible precipitate.

Figure 5: (a) Diagram of the Ouchterlony assay. (b) Two rosettes punched into an agarose
gel. In the central well of each rosette, antisera is loaded. In the rosette to the right, the
top well was loaded with a positive control; the bottom well was loaded with a negative
control and the two side wells were loaded with sample extract. Both samples and the
positive control produced a positive reaction as indicated by the visible white precipitate
line. The negative control is negative as it lacks a visible precipitate between it and the
antisera well.
9

1.1.2 Presumptive and Confirmatory Detection of Semen

Semen is comprised of a cellular component, spermatozoa (sperm cells), leukocytes
and epithelial cells, as well as a fluid portion. During spermatogenesis, spermatozoa are
formed in seminiferous tubules in the testes. Spermatozoa are then transported to the
epididymis where they mature, a process that takes approximately three months. During
ejaculation, sperm cells leave the epididymis through the vas deferens where they can
ultimately join with secretions from glandular tissues. An average ejaculation produces 25 mL of semen containing 107 to 108 spermatozoa per milliliter. Sperm cells account for
only 1-5% of the total ejaculate volume [9].
Human spermatozoa are comprised of three regions, the head, the midpiece, and
the tail. The head contains the nucleus which contains a single set of chromosomes from
the male. The acrosomal cap surrounds the very tip of the head. The acrosomal cap
contains lytic enzymes that aid in the digestion of the outer membrane of the ovum,
allowing for sperm penetration. The midsection connects the head to the tail. This is where
the mitochondria that generate ATP to provide energy for tail movement are localized. The
tail itself contains microfilaments that contract to provide forward motion.
Seminal plasma is a complex fluid mixture made up of contributions from the
seminal vesicle, prostate and bulbourethral glands. Pre-ejaculatory fluid consists almost
entirely of secretions from the bulbourethral gland. This can contain traces of acid
phosphatase and prostate specific antigen. Less frequently, spermatozoa are observed and
these are thought to be due to carryover from a prior ejaculation. The bulbourethral gland
10

secretes mainly galactose used for energy and mucus production. Secretions from the
prostate gland account for approximately 30% of the ejaculate and include the enzyme acid
phosphatase, prostate specific antigen, citric acid, proteolytic enzymes and zinc. Both acid
phosphatase and prostate specific antigen are protein markers that are typically targeted for
the presumptive detection of seminal fluid. The seminal vesical contributes 65-75% of the
overall semen volume and secretes semenogelin proteins, flavins, fructose and
prostaglandins [10, 11]. Flavins are notable for their contribution to semen’s ability to
fluoresce under ultraviolet light – a property which is used to search for possible seminal
stains. Semenogelin I and II serve as additional targets for the immunochromatographic
detection of seminal fluid.
Chemical reaction-based assays such as the Barberio and Florence crystal tests have
also been used historically for the presumptive detection of seminal fluid. Due to their lack
of specificity and reproducibility however, they have been replaced with tests targeted to
enzyme activity and antibody-based detection of protein antigens. As previously stated,
prostatic fluid secretions include the enzyme acid phosphatase which has long served as a
presumptive marker for the detection of seminal fluid. Prostatic acid phosphatase cleaves
phosphate from substrates such as α-naphthol phosphate.

The resulting α-naphthol

undergoes an azo coupling reaction to form a pink/purple colored product indicative of a
positive reaction (Figure 6) [12].

As this reaction requires enzymatic activity, loss of

this activity over time due to such factors as microbial-associated protein degradation,
exposure to extremes of temperature and/or pH or inhibitory chemical agents can limit the
sensitivity and the time period during which this assay is useful.
11

While generally sensitive, this test is presumptive in nature as positive results can
also be generated by bacteria present in vaginal secretions as well as by endogenous acid
phosphatase produced by cervical epithelial cells. False positive results can also be
obtained with a variety of food products [13]. Several other acid phosphatase isoenzymes
have also been identified in human tissues aside from prostatic acid phosphatase. These
include erythroid acid phosphatase, lysosomal acid phosphatase, macrophage acid
phosphatase, and testicular acid phosphatase [3]. Elevated concentrations of acid
phosphatase in serum is seen (and used diagnostically) in patients with prostate cancer.

Figure 6: Acid phosphatase overlay used to detect seminal fluid stains on undergarments
such as those submitted in cases of alleged sexual assault. The purple/pink color indicates
the presumptive presence of acid phosphatase.
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Historically, the Ouchterlony assay as well as enzyme-linked immunosorbent
assays (ELISA) were used to detect seminal fluid protein markers such as prostate specific
antigen. During an ELISA assay for prostate specific antigen (PSA) which is also known
as p30, an anti-PSA antibody was bound to the bottom of wells on a polystyrene plate.
Sample extracts to be tested for the possible presence of PSA were then added to the wells.
Samples containing PSA allowed formation of a complex between the anti-PSA antibody
and the PSA antigen. A second anti-PSA antibody for a different epitope on the target
antigen was then added. This resulted in the formation of an antibody-antigen-antibody
sandwich in wells containing extracts from positive samples. An enzyme-conjugated antiimmunoglobulin antibody targeted to that second antibody in the sandwich was then added
to each assay well. This was designed to bind to the sandwich complex in wells with
extracts that were positive for PSA. The wells were then washed to remove any unbound
anti-immunoglobulin

antibodies.

Detection

of

any

enzyme-conjugated

anti-

immunoglobulin antibodies that remained bound to the sandwich complex (typically by
addition of an appropriate substrate for the conjugated enzyme) indicated a presumptive
positive result (Figure 7).
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Figure 7: ELISA assay for prostate specific antigen (PSA). (a) anti-PSA antibody
immobilized to the bottom of a well on a polystyrene plate. (b) PSA antigen from a positive
sample extract is added. (c) A second anti-PSA antibody for a different epitope is added
forming an antibody-antigen-antibody sandwich.
(d) enzyme-conjugated antiimmunoglobulin antibodies which are expected to bind only in positive wells allows for
detection of positive results.

In recent years, however, these techniques have been replaced by alternative
antigen-antibody assays based on immunochromatographic cartridges. The ABA p30
(Abacus Diagnostics), PSA SemiQuant® (Seratec), and RSIDTM Semen (Independent
Forensics) are three examples of commercially available assays for seminal fluid. The
ABA p30 and PSA SemiQuant® cartridges target p30/PSA while the RSIDTM Semen
targets semenogelin, a protein secreted by the seminal vesicle. Contrary to its name, PSA
is not specific to the male prostate. It can also be found in female vaginal secretions [14],
14

amniotic fluid [15], breast milk [16], and urine [17]. False positive results have also been
observed with semen-free vaginal (Figure 8) and postmortem rectal swabs [18]. Similarly,
semenogelin has been identified in kidney, colon and tracheal tissues as well as the sera of
lung cancer patients [3]. Moreover, non-specific binding events have been readily observed
to occur in the presence of organic acids.
(A)

(B)

Figure 8: Examples of putative false positive reactions from semen-free vaginal swabs
targeting semenogelin (A) and prostate specific antigen (B). Each set of four cartridges
includes one positive control and three test samples. Test lines indicating the presumptive
presence of seminal fluid proteins in semen-free vaginal swabs ranged from faint to
moderately strong.
15

Cellular components from a suspected seminal stain can be identified by
microscopy. Visual detection of human spermatozoa by a trained analyst is considered to
be confirmation of the presence of semen. Staining techniques such as the Christmas tree
stain (nuclear fast red and picroindigocarmine) or Sperm HyLiterTM (Independent
Forensics) are commonly used to facilitate the visualization of sperm cells (Figures 9-10).
Sperm HyLiterTM incorporates a fluorochrome-conjugated antibody into the staining
process. This antibody is targeted to a nuclear membrane protein in spermatozoa [19]. The
greatest advantage to microscopic visualization techniques for the identification of semen
is its confirmatory nature. However, the staining process and visualization of samples can
be time consuming. Sperm HyLiterTM can reduce the search time needed to locate sperm
but it produces poor spermatozoa morphology with degraded samples. Additionally, these
techniques are not applicable to cases involving males who are vasectomized or suffer from
aspermia.

16

Figure 9: Spermatozoa visualized via light microscopy following the addition of Christmas
tree staining (nuclear fast red and picroindigocarmine).

Figure 10: Spermatozoa visualized via Sperm HyLiter staining in combination with
fluorescent microscopy (sperm and epithelial cells visualized under the DAPI filter
(LEFT), sperm cells visualized under the FITC filter (CENTER) and sperm and epithelial
cells visualized with an overlay (RIGHT)).
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1.1.3 Presumptive Detection of Saliva

Saliva is composed primarily of water but also contains electrolytes, buffers,
glycoproteins, antibodies and enzymes. Approximately 1.0-1.5 L of saliva is produced
daily by both serous and mucous acini cells, the basic secretory units of the salivary glands.
The three major salivary glands, the parotid, submaxillary and sublingual, produce
approximately 90% of saliva while the remaining 10% is produced by the minor salivary
glands. Saliva serves many roles in the body; it acts as a lubricant and binder to protect
the esophagus from masticated food, solubilizes dry food so that it can be tasted, flushes
the oral cavity of food and debris for oral hygiene and initiates starch digestion. The
enzyme α-amylase is the component of saliva responsible for cleaving the glycosidic bonds
of polysaccharide carbohydrates; thereby breaking them down into smaller oligo- and
monosaccharide molecules. Due to its abundance in salivary secretions, the detection of
α-amylase serves as the basis for the presumptive presence of saliva.
Several types of amylases have been characterized that differ based on their
mechanism of hydrolysis. The faster acting α-amylases require calcium as a cofactor and
act at random locations along a polysaccharide carbohydrate chain producing glucose and
maltose molecules. Mostly found in mammals, two isoforms of α-amylase exist – salivary
and pancreatic amylase. Encoded by the Amy1 and Amy2 loci respectively, the amino acid
sequences of these isoforms are highly homologous and therefore difficult to distinguish
from each other. Found mostly in plants, fungal and bacterial sources, β-amylase moves
from the non-reducing end of polysaccharide carbohydrate catalyzing the hydrolysis of
18

every other α-1,4 glycosidic bond to yield maltose molecules [20]. A third isoform, γamylase, hydrolyzes α-1,6 glycosidic linkages and unlike the other isoforms of amylase,
will continue to function in acidic environments [21].
A common presumptive test for saliva is an enzyme activity-based test for amylase
called the starch-iodine radial diffusion test. For this assay, starch is incorporated into a
gel matrix. Suspected saliva stains are then allowed to incubate within wells in this matrix.
Through passive diffusion, the amylase in saliva will cleave starch molecules into
oligosaccharides within the gel matrix surrounding the well. Iodine is then used to stain
the gel as iodine reacts strongly with amylose in starch to form a dark blue complex. Any
clear areas around wells of the gel indicate a lack of starch and therefore the presence of
amylase activity. The size of the clear “halo” around the well can be correlated to the
amount of amylase activity in a sample (Figure 11). This test, however, is not specific to
α-amylase as it will also react with β-amylase, which as previously indicated, is present in
plant and bacterial sources. In addition, small amounts of amylase enzyme present in body
fluids other than saliva, e.g., breast milk [22], sweat, tears, semen [23], vaginal fluid and
feces [24] are also capable of yielding positive results..
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Figure 11: Starch radial diffusion test. The clear wells indicate the presence of amylase.
The larger the radius of the clear area around the well, the greater the concentration of
amylase activity.

Additional assays that test for amylase activity include the Phadebas® test (Magel
Life Sciences) and the SALIgAE® test (Abacus Diagnostics) [25]. These are colorimetric
assays that utilize insoluble dye-labeled amylase substrates. When a suspected saliva stain
is assayed, amylase activity will cleave the dye-labeled amylase substrates, forming smaller
soluble saccharide molecules.

This allows for dye solubilization and thus color

development indicating the presence of amylase activity (Figure 12).
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These assays are

again considered presumptive as they are not specific to human salivary α-amylase and
have the potential to react with the variety of substances and non-saliva body fluids listed
above which also contain amylase.

Figure 12: The smear of pale blue in the center of the substrate indicates the presumptive
presence of saliva using the Phadebas® test.

Commercially available immunochromatographic assays for saliva include the
RSIDTM Saliva (Independent Forensics) test [26]. This assay employs monoclonal antihuman salivary α-amylase antibodies conjugated to colloidal gold particles (typically)
within the sample well. A second monoclonal anti-human salivary α-amylase antibody is
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immobilized at the test zone of the cartridge. Positive results from non-saliva samples
reported in the literature for this assay include breast milk, urine, feces, semen and rat saliva
[23, 26, 27]. ELISA as well as the Ouchterlony assays, both described previously, can also
be used to detect human salivary α-amylase as well as statherin which is another saliva
biomarker protein [28, 29]. As with any antibody-based assay, unpredictable crossreactivity with non-target molecules having similar conformational epitopes is a concern
as are non-specific binding events due to extremes of pH or other sample-specific chemical
compounds which may lead to false positive reactions.

1.1.4 Presumptive Detection of Urine and Fecal Matter

Urine is composed primarily of water but also contains organic molecules, ions,
leukocytes and epithelial cells. The kidneys are responsible for the formation of urine
which removes the waste products of cellular metabolism. Urea, an end-product of protein
degradation, is one of the most abundant waste components of urine. Creatinine, a product
of muscle metabolism, is another major waste product found in urine. A number of
chemical reaction-based assays as well as enzyme-activity based assays have been
developed to test for the presence or both urea and creatinine.
Urea can be detected with the Nessler’s reagent. In this assay, urease is used to
catalyze the hydrolysis of urea to liberate ammonia and carbon dioxide. The production of
ammonia is detected with Nessler’s reagent (potassium hydroxide, mercuric iodide and
potassium iodide) through the formation of an orange/brown precipitate.

Ammonia

formation following urease application has also historically been detected using
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bromthymol blue, an acid base indicator that turns blue in the presence of urine. Manganese
and silver nitrates, which turn black in the presence of urine, have also been used.
Alternatively, para-dimethylaminocinnamaldehyde (DMAC) has been used to directly
detect urea based on the formation of a pink/red color in its presence. However, none of
these methods described are specific to urine.

Other bodily fluids namely vaginal

secretions, semen, saliva, and sweat can all produce positive reactions [30]. Historical use
of microscopic crystal assays for the detection of urea and converted urea nitrate crystals
can also be found in the literature [5].
Creatinine can be detected using a colorimetric reaction called the Jaffe color test.
During this test, the addition of sodium hydroxide and picric acid are used to convert
creatinine to creatinine picrate which forms a yellow/orange precipitate. Recently, a test
cartridge called Uritrace (Abacus Diagnostics) has become commercially available for the
detection of creatinine. This test also employs a colorimetric mechanism of action. The
Salkowski test was another historically used colorimetric reaction in which sodium
nitroprusside reacted with creatinine upon heating to form a blue product. As with other
urine assays, these reactions suffered from specificity limitations. While found in higher
concentrations in urine, creatinine is not specific to urine. During muscle cell metabolism
creatinine is formed through the metabolism of phosphocreatine through an intermediary
and creatine released into the blood. From there it is filtered by the kidneys into urine for
excretion. As a result, it can be detected in blood as well as semen. Additionally, the
amount of creatinine present in the urine is directly proportional to an individual’s muscle
mass resulting in high interindividual variability in detection sensitivity.
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RSIDTM Urine (Independent Forensics) targets the most abundant protein in urine,
uromodulin or Tamm-Horsfall glycoprotein. Tamm-Horsfall glycoprotein is synthesized
in the epithelial cells of the loop of Henle (ansa nephroni) and secreted into the lumen.
Historically, an ELISA assay was used to detect Tamm-Horsfall glycoprotein. As with
most of the other currently employed serological tests mentioned above, however, these
assays are presumptive in nature as urine from non-human species as well as synthetic
urine and a number of other commercial products have been found to produce positive
reactions (Figure 13).

Figure 13: False positive result using an RSID TM Urine assay following the addition of
Coca Cola in the absence of urine.

Fecal material is comprised mostly of undigested food, water and bacteria. The test
for fecal matter, known as the Edelman test, identifies the presence of urobilinogen, a
product of bilirubin reduction formed in the intestines. Mercuric chloride has historically
been used to oxidize urobilinogen to urobilin which in turn forms a zinc-urobilin complex
in the presence of alcoholic zinc chloride. This chelated complex appears candy apple
green when viewed under UV light (Figure 14). This test cannot distinguish between
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human and other mammalian fecal material. Additionally, as urobilin is also present in
urine (albeit at lower concentrations), positive results can also be obtained with urine
samples. Therefore, this test is presumptive in nature. Additionally, visualization of the
chelated complex with UV light can be obscured by the presence of fats [3].

Figure 14: A positive result (LEFT) and negative result (RIGHT) using the urobilinogen
test for fecal matter.
1.1.5 Vaginal Secretions and Menstrual Fluid

Currently, there are no tests routinely used or that are commercially available for
the reliable detection of vaginal fluid in forensic laboratories. Historically, Lugol’s
staining of glycogenated epithelial cells of the vaginal wall was thought to provide an
indication of the presence of vaginal fluid. The iodine molecules in the Lugol’s stain fit
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into the helical structures that make up the glycogen molecule forming a dark brown
complex. However, this is no longer considered to be specific for vaginal cells as it is
difficult to differentiate vaginal and buccal epithelial cells with this stain [31].
Glycogenated epithelial cells are also found in the lining of the anus, pharynx, esophagus,
urethra and glans penis [3]. Additionally, the amount of glycogenated cells in the vagina
varies with hormonal changes. High levels of estrogen support higher concentrations of
glycogenated cells, but these levels drop with menstruation, in pre-pubescent and postmenopausal women. Fluctuations in the levels of glycogenated cells have also been
observed during pregnancy and in association with the use of hormonal contraceptives.
The Dane’s staining method has also been evaluated as a means of differentiating
glycogenated epithelial cells originating from the vaginal versus the oral/buccal cavity.
When applied, the Dane’s stain (a mixture of hemalum, phloxine, Alcian blue, and orange
G) generally stains buccal cells orange/pink with red nuclei (although this showed
considerable variability within and between individuals) and stains vaginal cells bright
orange with orange nuclei. The Dane’s stain will also stain epithelial cells from skin (cells
which often lack nuclei) red and orange [3]. While pure samples of vaginal, epithelial, and
buccal cells can be readily differentiated with the Dane’s stain, mixtures of these cell types
could not be reliably distinguished. As a result, this histological staining approach has
limited applicability when working with forensic samples.
During menstruation, blood and the degenerated lining of the endometrium from
the uterus are sloughed off and eliminated from the body. Blood loss is controlled through
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a balance of blood coagulation and clot dissolution that allows for removal of tissue
fragments from the uterus. During clot dissolution, cross-linked fibrin is cleaved by the
enzyme plasmin, producing a degradation product, D-dimer, in the process. An ELISA
assay can be used to detect the D-dimer. Additionally, Seratec PMB is a recently developed
immunochromatographic multiplex assay that allows for the simultaneous detection of
human hemoglobin and D-dimer for the differentiation between peripheral blood and
menstrual fluid [32]. While D-dimer is present in peripheral blood, it is found at much
lower concentrations which are generally below the detection limits of these assays.
However, postmortem blood contains higher levels of D-dimer and thus can produce a
positive result in the absence of menstrual blood.
Historically, lactate dehydrogenase (LDH) detection was also used for the forensic
identification of menstrual fluid. LDH plays a major role in glycolysis. Five LDH
isoenzymes can be found in blood, each composed of four subunits with various
combinations of subunit A and subunit B. For example, LDH1 is composed of four
identical B subunits while LDH5 is composed of four identical A subunits (Figure 15).
Each of the five isoforms can be differentiated based on differences in mobility using
electrophoresis [33]. Typically, LDH1, LDH2 and LDH3 are predominantly observed in
peripheral blood while LDH4 and LDH5 are predominantly observed in menstrual fluid.
As LDH levels can fluctuate and can be found in other tissues, the forensic utility of this
test for menstrual fluid is considered to be limited at best [34].
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Figure 15: Five isoforms of lactate dehydrogenase (LDH) found in blood. Each isoenzyme
is composed of four subunits. Isoenzymes differ from one another based on the specific
combinations of the A and B subunits.
1.2 Future Serological Techniques

Given the substantial limitations associated with current serological techniques,
several novel approaches to identifying biological fluids have been explored in recent
years. These include the use of epigenetic modifications, messenger RNA markers, micro
RNA expression patterns, and high-specificity protein biomarkers. Of these, epigenetics
has also been used in an effort to predict age signatures from biological fluids. All of these
emerging techniques aim to improve the sensitivity and specificity of forensic body fluid
identification while allowing for rapid sample analysis and easy adoption by analysts in a
case-working environment.

1.2.1 DNA Methylation Assays for Body Fluid Identification

Epigenetics is the study of potentially transmissible modifications to DNA that are
typically associated with changes in DNA methylation that leads to changes in gene
expression. Methylation of cytosine residues, typically located at CpG islands in promoter
regions upstream of genes, enable gene silencing [35].
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Conversely, unmethylated/

undermethylated promotor regions of genes allow for the transcription of genetic
information.

Methyltransferase is responsible for in vivo cytosine methylation by

transferring a methyl group from S-adenosylmethionine to cytosine at the carbon-5
position. Tissue-specific patterns of DNA methylation have shown promise as a means of
body fluid identification.
This technique relies on detecting these tissue-associated differences in methylation
pattern.

For example, several regions have been found that are consistently

hypomethylated in cells from seminal fluid as compared to other biological fluids.
Typically, bisulphate conversion is used to convert un-methylated cytosine residues to
uracil via hydrolytic deamination (Figure 16). Methylated cytosine residue specific PCR
primers can then be used to amplify targeted regions of interest. Alternatively, methylation
specific restriction enzymes can be used to cleave DNA at unmethylated sites, leaving
methylated DNA intact. The polymerase chain reaction can then be used to amplify intact,
methylated DNA while the cleaved, unmethylated regions are not copied. Another
technique for isolating methylated DNA is methyl-DNA immunoprecipitation.
Antimethylcytosine antibodies are used to bind methylated cytosines on sheared DNA
which can then be isolated via immunoprecipitation.
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Figure 16: Bisulphate conversion of 5-methylcytosine.

Blood (based on the FOX03 and EFS genes) [36], saliva (based on the SLC12A8
and BCAS4 genes), semen (based on the DACT1 and C12orf12 genes) [37] and skin cells
have all been successfully identified using methylation-based tissue identification [35].
More recently, tissue specific differentially methylated regions have also been identified
for vaginal secretions (based on the LOC404266 and HOXD9 genes) and menstrual fluid
(based on the LC26A10 and LTBP3 genes), allowing for its differentiation from peripheral
blood [32]. Positive results have also been generated for casework-type samples for semen
and bloodstains that had been aged for up to 20 months. A commercial assay for the
detection of seminal fluid, Nucleix DSI-Semen kit, has been developed and validated [38,
39]. Multiplex testing has recently been published but not yet commercialized [40, 41].
A potential advantage of this assay is that it can easily be incorporated into the
existing DNA workflow for most operational forensic laboratories. Additionally, the
multiplexed analysis of different body fluids in one assay is possible and would eliminate
the need for multiple separate tests to be performed on the same sample for each biological
fluid of interest. This would save time and sample as well as eliminate the need for analysts
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to be trained and to stay proficient in multiple analytical techniques. Further research,
however, is still needed in order to assess how methylation patterns change in response to
certain factors such as environmental stimuli, aging and disease as well as to evaluate the
degree of inter-individual epigenetic variation [42] that exists with human populations.
While epigenetic modifications associated with DNA from seminal fluid has been
shown to be robust and reliable, the pattern of varying degrees of methylation in other
bodily fluids makes interpretation of results, especially in mixed fluid samples, complex.
Furthermore, while techniques such as DNA methylation microarrays and genome bisulfite
sequencing allow for the detection of enough multiplexed targets to be forensically
informative, these approached require large quantities of high-quality DNA. This may not
be feasible for many forensic samples that are often present only in trace amounts or have
been subjected to environmental degradation. Alternative techniques such as methylation
quantitative PCR and bisulphate pyrosequencing are more amenable for lower
quality/quantity input but these approaches are more limited in terms of their multiplexing
capabilities [43, 44].
As mentioned previously, methylation patterns have been found to be susceptible
to change due to the natural aging process. To detect methylation, targeted bisulfite
conversion detected with a SNaPshot assay or pyrosequencing has been the method of
choice. The bisulfite conversion deaminates non-methylated cytosine and converts it to
uracil (PCR amplification converts this to thymine) while methylated cytosine is
unaffected.

The SNaPshot assay can be used to detect single base differences by
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incorporation of terminating dideoxynucleotide triphosphate bases. Extension products
can then be analyzed using capillary electrophoresis (Figure 17).

The percent of

methylation can then be estimated by dividing C/G intensity (unconverted methylated
DNA) by C/G plus T/A (bisulfite converted unmethylated DNA) intensities. Review of
online databases of genome-wide methylation profiling (most commonly from Illumina’s
Human Methylation Bead Chip technology) has been used to identify candidate target
methylation sites [45].
To build age prediction models, samples of a particular biological fluid are
collected from individuals spanning gender, ethnicities and chronological age.
Multivariate linear regression coefficients and significance of correlation between
chronological age and DNA methylation ratios can then be used to identify promising
targets for age prediction [45]. These accumulated methylation changes associated with
age may be tissue specific. Studies have demonstrated that different sites are better
correlated with age in specific tissues. Therefore, multiple sites within a specific tissue
which correlate with the aging process for that particular tissue type will need to be
identified.
For example, in one study methylation of a CpG site, PRMT2, showed no
correlation with age in saliva or semen samples. However, this epigenetic marker was
found to be age associated in blood samples [35]. In another study, two epigenetic markers
in the TTC7B gene and one additional epigenetic marker in the NOX4 gene showed a high
correlation between predicted and chronological age in semen samples [45]. An additional
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six age-associated CpG markers on the SST, CNGA3, KLF14, TSSK6, TBR1 and SLC12A5
genes have been identified in saliva [46]. Multiple other markers have been identified in
blood samples from individuals of varying age and ethnicity that correlate to age prediction
– typically with an estimate of error of between 3 to 6 years [47].
While this work looks promising, the identification and application of DNA
specific methylation patterns as a predictive tool for age estimation is still in the early stage
of development. Additional areas of research have been focusing on combining epigenetic
analysis and next generation sequencing approaches for body fluid identification. It is
thought that this may provide additional supporting evidence for predictive age signature
applications [48].
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Figure 17: Illustration of bisulfite sequencing of cytosine methylation where unmethylated
cytosine is converted to uracil. PCR and sequencing then ultimately convert cytosine to
thymine; thereby indicating the site was unmethylated.

1.2.2 RNA Based Assays for Body Fluid Identification

Messenger ribonucleic acid (mRNA) is the product of transcription that conveys
genetic information from DNA to the ribosome for translation where it specifies the amino
acid sequences of the protein products of gene expression.

Just as tissue specific

differentially methylated regions of DNA were identified for the epigenetic identification
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of biological fluids, tissue specific gene expression has been targeted for mRNA-based
assays. These assays seek to detect mRNA transcripts that are exclusive to certain cell and
tissue types.
A major advantage to mRNA body fluid analysis is that it uses standard techniques
and instrumentation already widely implemented in forensic biology laboratories. The two
most common techniques used for mRNA body fluid analysis are reverse transcription
followed by end-point PCR and capillary electrophoresis as well as reverse transcription
coupled with quantitative PCR (qPCR). During reverse transcription, a complementary
DNA (cDNA) is produced from an mRNA template by reverse transcriptase. Primers for
established body fluid-specific gene transcripts are incorporated during a multiplex or
several singleplex PCR reaction(s) and the resulting amplicons are analyzed via capillary
electrophoresis.

The expression of multiple mRNA markers is used to deduce the

biological source of a particular sample [49]. Alternatively, cDNA can be amplified via
quantitative PCR. During qPCR, pre-designed target-specific primers and TaqMan (or
similar) probes can be used to quantify gene expression [50-52]. Reverse transcription
coupled with end-point PCR and capillary electrophoresis or qPCR are sensitive techniques
for quantifying mRNA expression in samples, however, the degree of multiplexing is
limited. As a result, only a few mRNA biomarkers can be assayed in a single reaction.
To identify novel body fluid specific markers and better understand the gene
expression variation between forensically relevant body fluids, whole transcriptome
analysis was needed. DNA microarrays has been useful in these discovery projects. In
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one approach, oligonucleotide probes are attached to or synthesized on the solid surface of
a chip. These are then hybridized to cDNA or RNA strands of interest. Fluorophores can
be used to detect probe-target hybridization events [53, 54]. Subsequent analyses of geneexpression profiles in populations of study subjects have identified multiple tissue-specific
mRNA markers for those body fluids most frequently encountered in forensics.
For example, HBA1 (alpha 1 hemoglobin), HBB (beta hemoglobin), SPTB (beta
spectrin) and PBGD (porphobilinogen deaminase) are a few of the mRNA markers
reported to be “specific” to peripheral blood. Similarly, HTN3 (histatin 3), MUC7 (mucin
7) and STATH (statherin) are mRNA markers reported to be “specific” to saliva. The
KLK3 (prostate-specific antigen), PRM1&2 (protamines 1 & 2), and SMG1 (semenogelin
1) transcripts have been proposed as specific mRNA markers for seminal fluid; HBD1
(beta defensin 1) and MUC4 (mucin 4) transcripts have been proposed as -“specific”
markers for vaginal secretions; and the MMP7 and 11 (matrix metalloproteinase 7 and 11)
transcripts have been proposed as “specific” markers menstrual fluid. A large number of
studies in the published literature have assessed the potential utility of these mRNA
markers [50, 55-59]. In addition to the tissue-specific gene transcripts used for body fluid
identification, a number of consistently expressed housekeeping genes have also been
proposed for use as internal controls [52]. Recently, a commercial product, ParaDNA®
Body Fluid ID System, has been developed. This portable device targets mRNA markers
for seminal fluid, sperm cells, vaginal fluid, saliva, blood and menstrual fluid [60].
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While these assays and commercially available tests are more specific than current
testing methodologies, they suffer from the general stability limitations of any work
involving mRNA targets. Degradation due to endogenous ribonucleases frequently effect
mRNA stability in biological samples. Additionally, crime scene samples are often
exposed to ultraviolet light, moisture and wide temperature ranges – all of which can lead
to mRNA degradation in biological fluid samples. However, body fluids have been
successfully detected using mRNA markers in aged samples that have been maintained
under appropriate storage conditions.
In an effort to address the stability concerns associated with larger mRNA
transcripts, microRNAs have been evaluated as an alternative type of RNA biomarker.
MicroRNAs, which regulate gene expression, are much smaller and more abundant than
mRNAs. While this makes them more stable targets, the expression of microRNAs is more
ubiquitous.

Thus, although broad expression patterns characteristic for forensically

relevant fluids can be identified, the interpretation of body fluid mixtures continues to
poses a formidable challenge [61, 62].

1.2.3 Proteomic Based Assays for Body Fluid Identification

A particularly promising approach for the serological identification of biological
fluids combines high-specificity protein biomarkers with mass spectrometry. This allows
for the direct identification of target proteins (even in partially degraded samples); true
confirmatory identification and greatly enhanced sensitivity.
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A proteome is the full complement of proteins present in an organism while
proteomics is the study of these expressed proteins. Protein biomarkers have attracted
significant interest in recent years due in large part to the strides that have been made in
the tools available to identify and characterize them. It is now possible to rigorously map
entire proteomes with high reproducibility. Techniques such as differential 2-D gel
electrophoresis or multidimensional protein identification technology (MudPIT) [63, 64]
have made it possible to identify a vast number of candidate protein biomarkers [65-68].
Once potentially useful candidate protein biomarkers have been identified, massspectrometry-based targeted-ion assays can facilitate the unambiguous detection and
quantitation of even low abundance biomarker protein targets against a background of
other non-target molecules in complex biological matrices [63, 69, 70].
This has resulted in a wealth of new opportunities to develop protein-based assays
for both medical and forensic applications.

Most forensic approaches for stain

identification follow a “bottom-up” shotgun approach to biomarker detection and
identification. In this approach, a complex biological sample is first enzymatically cleaved
and small peptides (~15 amino acids in length) are the fractionated by liquid
chromatography followed by identification of protein targets of interest using tandem mass
spectrometry [71].
One of the significant advantages of a protein biomarker approach is the diversity
of potential targets that are made possible due to post-translational modification in different
tissues. Another key advantage is the stability of many proteins under conditions that lead
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to degradation of other biological macromolecules. Proteins are among the most longlasting of all biological molecules having been routinely isolated from even ancient
biological material [72] and post-mortem tissue [73]. Even when degradation begins to
occur, simple modification of detection methodologies focusing on the detection of
fragmented proteins still allows for reliable detection.

1.3 Research Objectives

This dissertation research was designed to develop and assess the potential utility
of a targeted-ion Triple Quadrupole Mass Spectrometry in Multiple Reaction Monitoring
mode (QQQ-MRM) approach for the identification of biomarker targets specific to
forensically relevant biological fluids. The application of this technology, especially for
the front-end processing of sexual assault evidence, has been a central focus of this
research. To achieve this, selected biomarkers from previous studies were incorporated into
a multiplex QQQ-MRM method for the simultaneous detection of up to six biological
fluids. The subsequent developmental validation of this QQQ-MRM assay provided
forensic analysts with a high level of confidence in the accuracy of the results obtained.
This multiplex assay was then used as a foundation for the development and
optimization of a monoplex QQQ-MRM assay for semen, with the goal of using this for
the high-throughput analysis of sexual assault samples. This was achieved by eliminating
from the larger multiplex assay all biomarker peptides not specific to semen. Doing so
maximized the dwell time efficiency of the instrument; thereby increasing the assay’s
detection sensitivity for seminal fluid targets. Assay specificity was assessed by analyzing
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a series of mixtures consisting of saliva, semen, vaginal secretions, urine, peripheral and
menstrual fluid. The extent to which the optimized monoplex QQQ-MRM assay for semen
can extend the post-coital interval for the detection of seminal fluid in cervico-vaginal
samples

was

then

assessed

relative

to

the

results

obtained

with

the

immunochromatographic assays currently employed by forensic laboratories.
The qualitative monoplex assay for seminal fluid detection was then further
modified to develop an absolute quantitation QQQ-MRM assay for seminal fluid. By
establishing the limit of detection (LOD) and quantitation (LOQ) for the assay, the
relationship between quantitative levels of target seminal fluid peptides and the ability to
generate male-targeted Y-chromosome short tandem repeat (Y-STR) haplotypes from
vaginal swabs collected at various post-coital intervals was assessed. The quantitative
monoplex assay was also used to estimate of the rate of authentic false positive results
associated with immunochromatographic assays that target the same proteins quantitated
by the QQQ-MRM method. The successful completion of these objectives has important
implications for the successful prosecution of the perpetrators of sexual assault as well as
the effective defense of those who are wrongly accused.

1.4 Hypotheses

The overarching hypothesis that was tested in the course of this dissertation
research is that a targeted-ion mass spectrometry based proteomic assay would provide for
the sensitive and specific identification of biological fluid specific protein targets
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(especially as compared to currently employed immunochromatographic based serological
assays). The specific hypotheses that were at the core this research therefore are:
1.

The use of a mass-spectrometry based assay for seminal fluid will surpass the
sensitivity levels of the antibody-based assays employed by most forensic
laboratories.

2. The accuracy, reliability and enhanced sensitivity of the proposed assay will extend
the post-coital interval during which it is reasonable to collect sexual assault
samples that are likely to yield useful results.
3. A quantitative mass-spectrometry based seminal fluid assay will make it possible
to assess the likelihood of obtaining a useful Y-STR haplotype based on the
quantity of seminal fluid biomarkers present on the post-coital swab (i.e., the ability
to use protein quantities in the same way as DNA quantitation data is currently used
to screen samples for downstream DNA profiling).
4. The accuracy and enhanced sensitivity of a QQQ-MRM assay for semen proteins
can be used to independently assess the rate of actual false positive results (i.e.,
non-specific binding events) associated with the antibody-based lateral flow tests.

1.5 Dissertation Structure

Within each chapter of this dissertation an introduction will establish the necessary
background content and justification for the given set of experiments. A description of the
experimental methods will be provided and a summary of all pertinent results will be
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detailed. Each chapter discusses the significant research findings that were made including
any caveats relevant to adoption by forensic practitioners in an operational environment.
Chapter 2 focuses on highlighting one of the inherent limitations associated with
the most commonly employed serological method in forensic laboratories. Namely, this is
the well-documented lack of specificity that has been encountered with the use of
immunochromatographic assays. Chapter 3 focuses on the developmental validation of an
MRM method for the concurrent identification of six biological fluids of forensic interest.
Chapter 4 assesses the feasibility of a mass spectrometry-based body fluid assay for the
analysis of sexual assault samples by narrowing the scope of the assay to seminal fluid in
order to maximize assay sensitivity. Chapter 5 focuses on how a quantitative (versus
qualitative) method for seminal fluid detection can be used to establish true false positive
rates for common immunochromatographic assays that target prostate specific antigen and
semenogelin proteins. Chapter 5 also focuses on the use of semen protein quantitation by
mass spectrometry for the reliable prioritization of samples for downstream genetic testing.
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CHAPTER 2: FALSE POSITIVE IMMUNOCHROMATOGRAPHIC TEST
RESULTS ASSOCIATED WITH ORGANIC ACIDS

2. Introduction

The ability to detect biological fluids recovered from a crime scene can provide
useful information for the investigation of a crime. Specifically, this information may be
used to prioritize testing of items of evidence, direct downstream testing methodologies for
the development of genetic profiles, or to provide investigators contextual information
paramount to the criminal investigation.

In some instances, being able to detect a

biological fluid on an evidentiary sample, even in the absence of genetic analysis, may be
sufficient to influence the outcome of an investigation and in some instances a court case.
It is therefore critical for forensic practitioners to be able to provide information on the
detection (or lack thereof) of a biological fluid as well as to be aware of the limitations
associated with the applied methodology. It is for this reason, that an increased emphasis
has been placed on developing serological tests that optimize sensitivity and specificity
while minimizing sample processing time so as to reduce the potential for backlogs in the
testing of crime scene evidence. One of the most common serological methods employed
currently in crime laboratories for the identification of biological fluids is the use of
immunochromatographic assays.
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Laminar flow immunochromatographic assays are commercially available from
multiple manufacturers and are commonly used in forensic practice to detect the presence
of bodily fluids including, blood, semen, saliva, and urine [1, 7, 26, 74-85]. These assays
employ labeled antibodies specific to a protein or other small molecular target considered
to be characteristic of (but not necessarily unique to) a given bodily fluid. When an extract
of a test sample is introduced to the sample well, the target antigen forms a complex with
mobile phase antibodies that are typically conjugated to colloidal gold particles. The
antigen-antibody complexes that form migrate down a lateral flow membrane.
Immobilized at a test site on the membrane are additional antibodies for different epitopes
on the same target protein that bind the complex forming an antibody-antigen-antibody
sandwich. Accumulation of the labeled antibodies from the sample well at the test zone
facilitates visual detection of target antigen. Labeled antibodies not captured at the test
zone continue to migrate to a control zone where they are captured by immobilized antiimmunoglobulin antibodies to form another visible line. This second visible line indicates
the test performed as designed. Sometimes, depending on manufacturer, an additional
control line is added making it possible to estimate the quantity of target protein in a
sample. While immunochromatographic assays represent a sensitive and efficient method
for forensic serological testing, the limitations associated with these assays must be fully
understood so as not to mislead investigators or the trier of fact.
Given their reliance on antibody binding reactions, these assays suffer from similar
types of limitations regardless of manufacturer. Depending upon the body fluid specificity
of the proteins used for any particular assay, there may be other non-target biological fluids
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that contain equal or lower concentrations of the target biomarker that are still capable of
producing positive reactions [7, 14, 15, 18, 26, 73, 86]. Additionally, while not as well
documented in the literature, chemically induced non-specific protein aggregation as well
as cross-reaction to structurally similar non-target antigens can both lead to false positive
reactions [18, 87]. One product’s user manual highlights the potential for non-specific
binding events by suggesting test results may be influenced by acidic pH in combination
with the presence of organic acids [88]. This study aimed to evaluate how pH and the
presence of organic acids may influence false positive results of multiple
immunochromatographic assays designed to target blood, semen, saliva and urine.
Immunochromatographic assays from multiple different manufacturers were
evaluated. Specifically, the ABAcard® p30 and ABAcard® HemaTrace® (Abacus
Diagnostics®); RSID™-Urine, RSID™-Semen, RSID™-Blood, and RSID™-Saliva
(Independent Forensics); and PSA Semiquant, HemDirect, and Amylase Test (Seratec®)
were evaluated. Citric acid and lactic acid were selected based on widespread use of these
organic acids in commercial products. Sample pH was adjusted to determine the degree of
pH dependence of false positive results with organic acids. Manufacturer-specific buffers
were utilized to evaluate their efficiency in mitigating false positive results. Common
household and commercial products that contain organic acids were also analyzed.
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2.1 Methods

2.1.1 Chemicals and Reagents

Citric acid (anhydrous) and lactic acid (85% pure) were obtained from Sigma
Aldrich (Allentown, PA). Hydrochloric acid (HCl) (36.5-38%) and 10N sodium hydroxide
(NaOH) were purchased from BDH Analytical Chemicals (Poole, United Kingdom).
Deionized water was obtained in house. All pH measurements were made using a Mettler
Toledo FiveGo pH/mV meter (Washington Crossing, PA).
RSID™-Saliva, RSID™-Semen, RSID™-Urine, and RSID™- Blood kits were
purchased from Independent Forensics (Hillside, IL).

ABAcard® p30 and ABAcard®

HemaTrace kits were purchased from Abacus Diagnostics (West Hills, CA). SERATEC®
PSA Semiquant, SERATEC® HemDirect Hemoglobin Test, and the SERATEC® Amylase
Test kits were purchased from Seratec® (Goettingen, Germany). See Table 1 for more
specific information pertaining to selected immunochromatographic assays evaluated in
this study. All reagents were stored according to manufacturer’s guidelines. Household
products and beverages that were evaluated for their potential to produce false positive
results included 1% cow’s milk, orange juice, white wine, apple juice, Monster Energy
drink, Windex®, Febreze, white vinegar, and Pine-Sol). These were purchased from local
retail outlets or voluntarily donated by laboratory staff.
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Table 1. Overview of Immunochromatographic Assays Evaluated.
Manufacturer

Seratec®

Abacus
Diagnostics,
Inc.

Independent
Forensics

Test

Target Antigen

Dye

PSA Semi-quant

Prostate Specific Antigen

Colloidal Gold

HemDirect

Hemoglobin

Colloidal Gold

Amylase

α-amylase

Colloidal Gold

ABAcard® p30

Prostate Specific Antigen

Possible Colloidal Gold,
Colloidal Silver,
Carbon, Latex, Dye,
Enzyme

ABAcard®
HemaTrace®

Hemoglobin

Possible Colloidal Gold,
Colloidal Silver,
Carbon, Latex, Dye,
Enzyme

RSID™-Semen

Semenogelin

Colloidal Gold

RSID™-Blood

Glycophorin A

Colloidal Gold

RSID™-Saliva

Salivary Amylase

Colloidal Gold

RSID™-Urine

Tamm Horsfall
Glycoprotein (Uromodulin)

Blue Latex Bead

2.1.2 Solution Preparation

A 0.3M citric acid solution was prepared by adding 5.76 grams of citric acid
anhydrous to 100 mL of deionized water. A serial dilution of the 0.3M citric acid stock
solution was used to prepare the following series of two-fold dilutions: 0.15M, 0.075M,
0.0375M, 0.0187M, and 0.0093M. A 0.3M lactic acid solution was prepared using 2.62
mL 85% pure lactic acid added to 97.38 mL of deionized water. All stock solutions were
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adjusted to a pH of 2 to 12 while dilutions were adjusted to pH 4 using HCl and NaOH
solutions. Neat citric acid and lactic acid solutions were determined to have a pH of 1.74
and 2.19, respectively.

2.1.3 Citric Acid and Lactic Acid pH Series Studies

The citric and lactic acid stock and dilutions were tested on all
immunochromatographic assays which included RSID™ Saliva, RSID™ Semen, RSID™
Urine, and RSID™ Blood kits; ABAcard® p30 and ABAcard® HemaTrace kits; PSA
Semiquant, HemDirect Hemoglobin Test, and the Amylase Test kits following the
manufacturer’s recommendations. Negative results on all assays were confirmed after 10
minutes. The dilutions that produced the last observable false positive result at both pH
extremes were performed in triplicate.

2.1.4 Deionized Water Study

To determine the potential effect of pH separate from that of organic acids,
deionized water was adjusted to a pH of 2 to 9. The pH values that generated a false
positive reaction with the citric acid stock solution (assay specific) and the acidified water
(pH 2) were assessed across all immunochromatographic assays.
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2.1.5 Kit-Specific Buffer Study

The citric acid stock solution (pH 4) was diluted 1:1 in kit specific assay buffer.
The resulting buffer-diluted organic acid solutions were then re-tested on the corresponding
immunochromatographic assay.

2.1.6 Common Beverages and Household Products

Household products or beverages were purchased from retail outlets or voluntarily
donated by laboratory staff.

All liquids were analyzed neat following individual

manufacturer guidelines. If a positive or invalid result was generated, the product was
diluted 1:1 with kit specific buffer and then re-analyzed.

2.2 Results

2.2.1 Citric Acid and Lactic Acid pH Series

The range of false positive results observed using the 0.3M citric acid stock solution
varied both by assay and manufacturer (Table 2). The Seratec® Amylase Test and RSID™
Urine assay generated false positive results over the widest pH range (between pH 1.74 –
11 and pH 3 – 12 respectively). For most other assays, solutions with extreme pH values
(pH 2 and pH 12) consistently produced invalid results. The ABAcard® HemaTrace®
generated the fewest false positive results (i.e., only pH 4 produced a false positive result).
Across all kits, the greatest frequency of false positive results was observed between pH 4
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and pH 10. Each test resulted in reproducible false positive responses when tested in
triplicate.
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Table 2. 0.3M Citric Acid Results for all Lateral Flow Assays Evaluated Over a pH Range
of 1.74 to 12.

Note: Not tested (NT); Positive (+); Positive confirmed in triplicate (+++); Negative
(NEG); Invalid (INV).

The pH ranges that generated false positive results for each assay differed between
citric and lactic acid (Table 3). Despite having readily generated false positive results with
citric acid solutions, neither the ABAcard® Hematrace® nor the SERATEC® HemDirect
assays produced any false positive responses in the presence of lactic acid. In contrast, the
Independent Forensics assays produced generally concordant results with 0.3M lactic acid
(pH 4 to 11) as compared to citric acid. The ABAcard® p30 and SERATEC® PSA
Semiquant assays produced false positive results with lactic acid only at acidic pH values
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(pH 2 to 4) despite producing false positive results at both acidic and basic pH values in
the presence of citric acid. False positive results demonstrated repeatability when testing
was performed in triplicate.
Table 3. 0.3M Lactic Acid Results for all Lateral Flow Assays Evaluated Over a pH Range
of 2.19 to 12.

Note: Not tested (NT); Positive (+); Positive confirmed in triplicate (+++); Negative
(NEG); Invalid (INV).

2.2.2. Citric Acid Dilution Series

A molarity of 0.3 was selected for the citric acid stock solution as this represents
the most concentrated molarity found in natural products (citric juices). A citric acid
dilution series was also assessed for the potential to produce false positive results (Table
4). Both the ABAcard® p30 and RSID™ Urine produced false positive results across the
entire dilution range evaluated. All other assays, with the exception of the SERATEC®
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HemDirect, produced false positive results down to a 0.0375M or 0.0187M solution. Of
particular note were the results obtained for the RSID™ Blood assay. Originally, this lateral
flow test generated a negative result with the 0.3M citric acid stock solution. However,
when diluted, the citric acid then produced in false positive results down to a citric acid
dilution of 0.0375M.

0.15M

0.075M

0.0375M

0.0187M

0.0093M

Abacus®
Diagnostics

Assay
ABAcard® p30

+

+

+

+

+

+++

ABAcard®
HemaTrace®

+

+

+

+

+/+/NEG

NEG

RSID™ Semen

+

+

+

+++

INV

NT

RSID™ Blood

NEG

+

+

+++

INV

NT

RSID™ Saliva

+

+

+

+++

INV

NT

RSID™ Urine

+

+

+

+

+

+++

PSA Semiquant

+

+

+

+

+++

NEG

HemDirect

+

+

+++

NEG

NT

NT

Amylase

+

+

+

+

+++

NEG

Seratec®

0.3M

Independent Forensics

Table 4. 0.3M Citric Acid Dilution Series Results for all Lateral Flow Assays Evaluated.

Note: Not tested (NT); Positive (+); Positive confirmed in triplicate (+++); Negative
(NEG); Invalid (INV).
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2.2.3 Deionized Water Study and Kit-Specific Buffer Studies

To assess the potential effect of pH in the absence of organic acids on non-specific
binding events of lateral flow assays, pH adjusted water samples were also assayed.
Acidified deionized water (pH 2) and median citric acid false positive pH values (kit
specific) were tested. No immunochromatographic assays produced false positive results
for pH adjusted water in the absence of an organic acid (Table 5).
The recommended best practice for testing liquid samples using immunochromatographic assays is dilution of questioned samples with kit-specific buffered solutions and
use of manufacturer-validated testing protocols. In all instances, with the exception of the
SERATEC® HemDirect and SERATEC® Amylase Test assays, dilution of the 0.3M citric
acid solution (pH 4) with kit specific buffers was insufficient in mitigating false positive
events (Table 5).
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Table 5. Immunochromatographic Assay Results with Deionized Water at Various pH
Values and with Kit Specific Buffer/Citric Acid Solutions.

Median H2O Result
(pH of water)

Acidified H2O
Result
(pH of water)

Kit Specific Buffer
Dilution Result
(1:1 Dilution of
0.3M citric acid)

ABAcard® p30

NEG (7)

NEG (2)

+

ABAcard®
HemaTrace®

NEG (4)

NEG (2)

+

RSID™ Semen

NEG (7)

INV (2)

+

RSID™ Blood

NEG (9)

INV (2)

+

RSID™ Saliva

NEG (7)

INV (2)

+

RSID™ Urine

NEG (7)

INV (2)

+

PSA
Semiquant

NEG (7)

NEG (2)

+

HemDirect

NEG (7)

NEG (2)

NEG

Amylase

NEG (7)

NEG (2)

NEG

Seratec®

Independent
Forensics

Abacus®
Diagnostics

Assay

Note: Deionized water at various pH levels in the absence of organic acids were tested on
all immunochromatographic assays (first two results columns). Results with each assay for
0.3M Citric Acid (pH 4) diluted 1:1 with kit specific buffer are illustrated in the third results
column. In all but two instances, the presence of kit specific buffer failed to mitigate false
positive results due to non-specific binding events. Positive (+); Negative (NEG).

2.2.4 Common Beverages and Household Products

Common commercial products containing organic acids were selected for
evaluation. Neat liquid samples were assayed first. In the event that a positive or invalid
test result was observed, a 1:1 dilution with kit specific buffer was also tested. All
immunochromatographic assays were found to generate a false positive result with at least
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one commercial product (Table 6). Apple juice produced the most false positive results
across all assays. Neat white wine and white vinegar generated the highest rate of invalid
test results. Dilution of these samples in kit specific buffer produced both negative and
false positive results depending on the assay. The ABAcard® HemaTrace® assay continued
to produce the fewest false positive results, only generating a positive reaction with white
wine and buffer diluted white vinegar. In over half of all instances, dilution of commercial
products with kit specific buffer failed to mitigate false positive results due to non-specific
binding events.
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Note: Not tested (NT); Positive (+); Negative (NEG); Invalid (INV).

Table 6. Results for immunochromatographic assays when tested with common commercial products
containing various organic acids (neat and diluted 1:1 with kit specific buffer).

2.3 Discussion

A lack of specificity was observed for all immunochromatographic assays
evaluated, regardless of target fluid or manufacturer. Findings from this study suggest it
is possible to obtain false positive results due to non-specific binding in the presence of
organic acids over a wide pH range. Therefore, the effects of organic acids do not appear
to be strongly associated with pH as has been previously suggested. Rather, these results
may depend in some cases on the strength of the organic acid being tested (12). Moreover,
the addition of kit specific buffer often fails to negate these unwanted results.

While

simple and sensitive, the possibility of false positive results due to non-specific binding
within immunochromatographic cartridges should be taken into consideration when
reporting results and conveying the potential significance of results to the trier of fact.
Doing so should help to prevent overstatement of the strength of the results obtained with
these assays (13, 26).
Assay sample well antibodies are bound to microparticles (e.g, colloidal gold)
through physical interactions involving non-covalent bonds which can be further
strengthened through the use of chemical linkers (27, 28, 29, 30, 31). The addition of an
organic acid may disrupt these bonds resulting in microparticles with reactive sites. As
these microparticles migrate past immobilized antibodies on the lateral flow strip, it is
reasonable to anticipate that these reactive sites could facilitate the aggregation of the
microparticles in the absence of the target protein. Regardless of mechanism, however, it
should be emphasized that the findings from this study demonstrate how lateral flow
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immunochromatographic tests can be greatly affected by non-targeted fluids, resulting in
a false positive reaction that cannot be visually distinguished from that of a true positive
result. Therefore, these data underscore the presumptive nature of immunochromatographic assays for forensic body fluid detection.
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CHAPTER 3: DEVELOPMENTAL VALIDATION OF A MULTIPLEX
PROTEOMIC ASSAY FOR THE IDENTIFICATION OF FORENSICALLY
RELEVANT BIOLOGICAL FLUIDS

3. Introduction

Current forensic methodologies for the identification of biological fluids still apply
many of the same analytical techniques that have been used historically for a century or
more; namely chemical reactions, color reactions produced as a result of enzymatic
activity, immunological reactions, or, in the case of semen, direct visualization of
spermatozoa by microscopy.

All of these techniques, however, suffer from not

insignificant test-specific limitations. Many of these tests are laborious, consumptive of
evidentiary material (especially when multiple tests in series are required) and necessitate
that analysts be proficient with a methodologically diverse range of laboratory techniques.
In addition, most existing serological assays suffer from low selectivity, limited specificity
and even when successful, produce only presumptive results, as highlighted in the previous
chapter.

For some body fluids (e.g., vaginal fluid, menstrual fluid and nasal mucus),

reliable serological assays do not currently exist – at least in the commercial space.
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Due in large part to the limitations associated with existing methods of biological
stain identification, several novel approaches to serological testing are being explored. A
preference for multiplex analysis that can simultaneously identify multiple body fluids
without the need for additional testing has been a long-standing desire by the community
of forensic practitioners. At the same time, the throughput demands faced by many forensic
laboratories necessitate that any novel procedures for body fluid identification be
compatible with current the protocols and overall workflow for DNA analysis. The
potential to bring greater standardization and automation to forensic serological testing is
akin to the type of progress that has been achieved over the past few decades in DNA
profiling.
This chapter reports the development and validation of a targeted proteomic method
for the simultaneous identification of forensically relevant biological fluids – namely
peripheral blood, semen, saliva, urine and vaginal/menstrual fluid. This method makes use
of Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) in Multiple Reaction
Monitoring (MRM) mode. This allows for the selective detection of a large number of
peptides derived from body fluid-specific proteins [63, 89, 90].
Previously, 2-dimensional HPLC has been used to identify candidate body fluid
specific protein biomarkers. Following enzymatic cleavage, target peptides of specific
amino acid sequences were selected for use in a target ion mass spectrometry. In the
present work, the most abundant and highly specific candidate peptide biomarkers for each
biological fluid of interest were evaluated via LC-MS/MS analyses to confirm their body
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fluid specificity in a sample population of at least fifty individuals. Following analytical
optimization and selection of product ion transitions for each target, a final multiplex MRM
method was designed to simultaneously and unambiguously identify six biological fluids
of interest. This targeted ion assay underwent rigorous developmental validation and its
forensic utility was demonstrated using simulated casework samples covering a wide
variety of sample types consistent with those encountered in an operational forensic
environment.

3.1 Methods

3.1.1 Chemicals and Reagents
HemogloBind™ was purchased from Biotech Support Group. Ammonium
Bicarbonate (ABC), Dithiothreitol (DTT), and Iodoacetamide (IAA), and 2,2,2Trifluoroethanol (TFE) were purchased from Sigma-Aldrich (St. Louis, MO). Mass
Spectrometry grade Trypsin Gold was sourced from Promega (Madison, WI). LCMS grade
water, acetonitrile, methanol, and acetone were purchased from Honeywell/Burdick and
Jackson (Muskegon, Michigan). All sample preparation was carried out in Eppendorf
LoBind Proteion microcentrifuge tubes. Absolute Quantification (AQUA) C-terminus
labelled peptides were custom synthesized by New England Peptide (Gardner, MA) and
delivered as lyophilized 2 nmol aliquots. Intact myelin basic and aprotinin stock solutions
(1 mg/mL) were purchased from New England Peptide (Gardner, MA) for use as internal
positive controls.
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3.1.2 Body Fluid Collection

Body fluids were collected in accordance with procedures approved by the
University of Denver’s Institutional Review Board for Research Involving Human
Subjects. Peripheral blood was collected via venipuncture into blood tubes containing
EDTA. Semen and urine were both separately collected by having donors deposit fresh
samples directly into sterile plastic specimen cups. Saliva was obtained by having
participants place Sarstedt Salivette™ saliva collection sponges into their mouths for 3-4
minutes. Sponges were then centrifuged for 2 min at 1500 RPM at 4°C to recover saliva.
Semen-free vaginal secretions and menstrual fluid were collected from participants who
had abstained from sexual contact for a minimum of 12 days. Vaginal secretions were
collected using a Softcup, which was placed in the vagina for a minimum of 1 hour then
removed and the collected fluids placed into a sterile specimen cup. The surface of the
Softcup was irrigated with 1mL ultrapure water and transferred into a 15 mL conical for
agitation by vortexing. Menstrual fluid was collected using a DivaCup® which was placed
in the vagina for a minimum of 1 hour during the first or second day of menstruation and
then removed and placed into a sterile specimen cup. The surface of the DivaCup® was
irrigated with 1mL ultrapure water and the resulting fluids were transferred into a 15 mL
conical for agitation by vortexing. Following collection and processing, all samples were
aliquoted into 1.5mL microcentrifuge tubes and stored at -80ºC. In general, and unless
otherwise indicated, 50 µl of blood or 125 µl of all other biological matrices were used for
the proteomic identification of target proteins.
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3.1.3 Casework-Type Samples

The applicability of a mass-spectrometry based body fluid assay to samples
encountered in a forensic context was assessed using a series of casework-type samples.
Specifically, the ability of the biomarkers to be detected in body fluid samples recovered
from a variety of substrates including cotton, denim, leather, metal, glass, plastic, sanitary
napkins and Styrofoam™ were tested. Similarly, the impact of exposure to environmental
contaminants/insults was also assessed. For these assays, aliquots of bodily fluids applied
to sterile cotton tipped applicators that had previously been dipped in such agents as 10%
bleach, neat bleach, soil, detergent, spermicidal lubricants, chewing tobacco, and soda were
used. Swabs designed to simulate sexual assault type evidence were also assessed. These
included oral swabs, rectal swabs, vaginal swabs, penile swabs and finger swabs. Finally,
a series of aged body fluids stored at room temperature for a period of 2-7 years were
analyzed.

3.1.4 Protein Extraction, Quantification, and Digestion

Dried stains were resolubilized by soaking in 400µL of diH2O for 30 minutes with
frequent agitation by vortexing. This was designed to facilitate the separation of biological
material from the substrate. Sample substrates were then transferred into clean spin baskets
and centrifuged at 14,000 RPM for 10 minutes. Fluid samples were centrifuged at 14,000
RPM for 10 minutes. If samples appeared to contain excessive quantities of hemolyzed red
blood cells, 400 µL of HemogloBind™ was added to selectively remove cell-free
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hemoglobin. Samples were vortexed for 30 seconds and mixed via inversion for 15
minutes prior to two centrifugation steps of 7,000 RPM for 2 minutes each. For samples
containing suspected denaturants (i.e., urea, detergents, etc.), precipitation using 1.2 mL of
acetone was carried out. Samples were vortexed, stored at -20 C for 30 minutes then
centrifuged in a refrigerated microcentrifuge at 12,000 RPM for 10 minutes at 4C. An
additional 600 µL of cold acetone was added to pelleted material and samples were stored
at -20 C for 15 minutes prior to centrifugation at 12,000 RPM for 10 minutes in a
refrigerated microcentrifuge at 4C. To resolubilize the pelleted protein, 150 µL of 50 mM
ABC was added and samples which were placed in a thermomixer set at 30 C and 850
RPM for 15 minutes. Samples underwent a final centrifugation step in a refrigerated
microcentrifuge at 4C at 12,000 RPM for 10 minutes. The resulting supernatant was then
transferred to a clean 1.5mL microcentrifuge tube for analysis.

Following sample

preparation protocols, total protein concentration was determined using a modified
bicinchoninic acid assay (Micro BCA Protein Assay, Thermo Scientific Pierce) using
bovine serum albumin as a known standard.
Following protein quantification, 20 µg of total protein was transferred to a 1.5mL
low retention microcentrifuge tube and lyophilized in a vacuum evaporator with the
addition of 16 pmol bovine myelin basic and aprotinin internal digestion controls. Dried
protein samples were reconstituted in 30 µL of denaturant buffer (50% TFE in 50 mM
ABC with 5 mM DTT) and incubated at 60 C with shaking (850 RPM) for 1 hour. The
resuspended proteins were then alkylated by the addition of 1.5 µL of 200 mM
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Iodoacetamide (IAA) and shaken in the dark for 30 minutes at room temperature.
Denaturant was diluted with 250 µL of 50 mM ABC and digested overnight at 37°C using
trypsin at a 50:1 protein/enzyme mass ratio. Digested samples were then lyophilized in a
vacuum evaporator and resuspended in 3% acetonitrile and 0.1% formic acid to a final
concentration of 0.5 µg/µl. Following digestion and purification, 10 µL labelled peptide
master mix, consisting of 0.4 pmol/µl AQUA peptide stocks in 30% acetonitrile with 0.1%
formic acid, were added to each sample.

3.1.5 LC-MS/MS Analysis

All samples were analyzed by LC-MS/MS on an Agilent Technologies HPLC-chip/MS
system coupled to an Agilent 6430 Quadrupole Mass Spectrometer operating in positive
dynamic Multiple Reaction Monitoring (dMRM) mode. Chromatographic separation was
carried using a high capacity chip containing a 150mm 300 Å C18 analytical column with
a 160 nL enrichment column. Columns were equilibrated in 0.1% formic acid in water.
Run conditions employed “Buffer A” (0.1% formic acid in water) and “Buffer B” (90%
acetonitrile, 10% water, 0.1% formic acid). An initial 30-minute run employed a gradient
of 3% Buffer B to 35% Buffer B over 24 minutes. This was followed by 5 minutes at 90%
Buffer B to flush the column and then reequilibration at 3% mobile phase A. A volume of
sample containing 1 µg of total protein was injected with a flow rate of 400 nL/min. This
assay targets a total of 26 individual precursor ions consisting of 6 peripheral blood
peptides, 5 saliva peptides, 6 seminal fluid peptides, 2 urine peptides and 7
vaginal/menstrual fluid peptides. Data were acquired through Mass Hunter software
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(Agilent Technologies v.B.04.01). Skyline software (v.3.1.0 MacCross Lab Software,
University of Washington, USA) was used for the in silico selection of peptide transitions,
optimization of collision energies as well as data analyses. Target peptide detection was
assessed as “positive” when all transition ions were detected at established ion and
retention time ratios for “natural/native” and “heavy” labeled internal standards were met
and peak morphology was of sufficient quality with a signal to noise ratio of at least 1:3.
At least one peptide of a biological fluid must be unambiguously identified in order to
positively identify the corresponding biological fluid.

3.2 Results

3.2.1 Confirmation of Body Fluid-Specific Targets

This study leveraged a database of preexisting targeted-ion data generated using
Quadrupole Time-of-Flight (QTOF) mass spectrometry. These data were generated in the
course of previously published biomarker validation studies by the Danielson research
group [90]. In an effort to ensure specificity, peptides and transitions were evaluated to
identify those that had a unique fragmentation pattern, were abundant, efficiently ionized
and had a mass to charge ratio greater than that of the tryptic peptide. Peptides with
interfering signals or those with a low response were eliminated from the list. Selection
based on these criteria was intended to yield an assay that would be both specific and
sensitive. A comprehensive list of target biomarker peptides and transitions for the
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detection of each of six human body fluids (i.e., urine, semen, saliva, vaginal/menstrual
fluid, and peripheral blood) is provided in Tables 7-11.
Table 7. Urine Biomarker, Peptide and Transition List.

Table 8. Seminal Fluid Biomarker, Peptide and Transition List.
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Table 9. Saliva Biomarker, Peptide and Transition List.

Table 10. Vaginal/Menstrual Fluid Biomarker, Peptide and Transition List.
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Table 11. Peripheral Blood Biomarker, Peptide and Transition List.

3.2.2 Development of a Multiplex Proteomic Assay for Body Fluid Identification

Optimized transitions for each target peptide as well as collision energy voltages
were initiated with in silico predictions using the Skyline Proteomics Environment
Software. To confirm optimized transition selection, the in silico settings were compared
to fragmentation spectra obtained experimentally through LC-MS/MS analysis of five
single-source reference samples for each target body fluid. Peak shape, abundance and
retention time were monitored in order to confirm the unambiguous detection of each
precursor-product ion pair. This information was used to evaluate the reliability with which
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transitions were detected. Synthetic peptides were used for the optimization of collision
energy voltage so as to avoid any possible matrix effects from the biological fluids of
interest at this stage of the validation process. Targeted-ion inclusion lists were compiled
for each biological fluid. Using saliva as an example, Figure 18 shows the total ion
chromatogram (A) and the MRM TIC for the target semenogelin-II peptides (B).

(A)

(B)
Figure 18: (A) Total ion chromatogram of a reference saliva sample with the percent
organic phase used in the gradient overlaid in red. (B) MRM ion chromatogram of saliva
with the percent organic phase used in the gradient overlaid in red.

Biological fluids, analyzed in duplicate, were then compared to synthetic peptide
reference standards to ensure consistency in ion ratios and retention time. These measures
were used to empirically verify that the assays actually identified the biomarker amino acid
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sequences they were designed to detect. While ion ratios were consistent between synthetic
peptides and biological fluids, slight shifts in retention times were noted in a small number
of samples. This phenomenon is not uncommon when working with nano flow systems.
To normalize for this, internal reference standards purchased from New England Peptide
(Gardner, MA) were used. These standards are synthesized with amino acid sequences that
are identical to target biomarker sequences but with the incorporation of stable “heavy”
isotope labels.

The stable isotope label behaves the same during HPLC separation but

produces a mass shift, which allows the standard and natural peptide from a sample to be
simultaneously monitored on the LC-MS/MS system (Figure 19).

Figure 19: Co-elution of an Absolute Quantitation (AQUA) peptide reference standard
and a natural peptide generated from a sample digest.
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Because forensic casework-type samples are typically of unknown composition
and/or may contain environmental contaminants or other compounds with inhibitory
properties that are co-extracted from evidentiary substrates, internal positive controls
(IPCs) are often incorporated into forensic biological chemistries. As it is reasonable to
assume that forensic samples may also contain enzyme inhibitors that may adversely
impact the efficiency of the proteolytic digestion of protein targets required for LC-MS/MS
identification, an IPC consisting of a trypsin-cleavable protein was incorporated into this
assay. Ideal IPC candidates have highly specific peptide sequences and would not likely
be found in casework-type samples. Ultimately, bovine myelin basic protein from bovine
brain was selected as an appropriate IPC. This globular protein was added to samples and
digested with trypsin alongside target proteins from biological fluids of interest. The
selected digest target (DTGILDSLGR) was evaluated in silico against the UniProt/SwissProt database to ensure that the sequences did not match any biomarker of interest as well
as any other protein sequence found in humans. The ratio between cleavage products
resulting from sample digestion and that of a non-radioactive “heavy” carbon isotope
labeled peptide of the same sequence was monitored during sample injections.
MRM is the ideal protein analysis detection mode because the mass spectrometer
is able to handle a large number of transitions per run without compromising sensitivity. A
single MRM method capable of simultaneously detecting all biological fluids was
developed after optimization and assessment of individual MRM methods for each fluid of
interest. The final multiplexed MRM assay included a total of 26 peptides and 88
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transitions. A comprehensive list of all selected peptide sequences, the m/z of their
precursor and product ions and optimized collision energies can be found in Appendix I.

3.2.3 Multiplex Validation

A series of developmental validation studies were conducted based on multiple
forensic community guidelines as applicable including the 2012 Scientific Working Group
on DNA Analysis Methods (SWGDAM) Validation Guidelines for DNA Analysis
Methods. These were designed to meet Standard 8.2 of the FBI’s “Quality Assurance
Standards for Forensic DNA Testing Laboratories”.

While these guidelines were

developed for the validation of DNA and RNA associated methods, they are in large part
applicable to the validation of novel target ion mass-spectrometry methods for serological
analyses.

In addition, the 2013 Scientific Working Group for Forensic Toxicology

(SWGTOX) Standard Practices for Method Validation in Forensic Toxicology were also
consulted and applicable guidelines followed to facilitate the design of a rigorous set of
validation studies.

3.2.3.1 Carry Over Study

The reliability of the developmental validation studies requires clean injections of
each sample such that the components of one injection do not interfere with subsequent
injections. In order to assess run-to-run carryover, proteins were extracted from neat body
fluids with the most abundant and hydrophobic markers (i.e., hemoglobin beta found in
peripheral blood and amylase found in saliva, respectively). These were injected at
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maximum column capacity (i.e., up to 1μg of total protein). Each “maximum protein” assay
was followed by a series of blank injections consisting of 3% acetonitrile, 0.1% formic acid
to monitor for sample carry over. No sample carryover was observed with blood digests
at the maximum loading capacity of the column (1μg). However, carryover of amylase in
saliva, which is both abundant and hydrophobic, was detected in the blank that followed
injection of 1μg of saliva digest (Figure 20). Carryover was not detected in the subsequent
injection (i.e., the second blank sample). Based on these results, a blank sample was
interspersed between all test samples for the remainder of the validation studies.

Figure 20: (TOP) Amylase peptide marker LSGLLDLALGK with 1ng saliva on column.
Note that the y-axis scale is in units of 105. (BOTTOM) Detection of trace amylase peptide
marker LSGLLDLALGK carryover in a subsequent blank injection on the LC-QQQ. Note
that the y-axis scale is in units of 102.
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3.2.3.2 Stability
Stability studies assessed the stability of targets and standards over extended time
periods on the instrument autosampler at room temperature (approximately 20 ºC). Pooled
samples from 10 donors were created for each biological fluid of interest. Samples
prepared in triplicate were analyzed for autosampler stability at time 0. These samples
were then left on the autosampler and reinjected for an additional 3 days. All peptide
targets for all proteins of interest demonstrated autosampler stability up to 3 days as
assessed on the basis of peak height intensity (Figure 21).

76

Figure 21: Autosampler stability data as measured by peak area of target peptides as a
function of days on autosampler. Two of the least abundant peptides based on sensitivity
studies are show for illustrative purposes. Note the apparent increase in peptide peak area
is most likely attributable to the progressive evaporation of the samples occurring over the
3-day period.

3.2.3.3 Sensitivity

Sensitivity studies were carried out to determine the range of body fluid quantities
that produced reliable results. For these studies, pooled samples from 10 human subjects
were diluted with 50 mM ABC. A series of 2-fold dilutions ranging from 1:1 to 1:262,144
were prepared in triplicate for each fluid. Results from these sensitivity studies are
presented in Table 12. The limits of detection for each target biological fluid varied in that
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peripheral blood peptide targets were the most sensitive (detection limit 1:262,144 or
0.0001μL of target fluid for hemoglobin), the urine peptide targets were least sensitive
(detection limit 1:128 or 0.3906μL of target fluid for uromodulin), and other fluids were of
intermediate sensitivity; semen (detection limit 1:16,384 or 0.0031μL of target fluid for
semenogelin II), saliva (detection limit 1:2,048 or 0.0244μL of target fluid for amylase),
and vaginal fluid (detection limit 1:1,024 or 0.0488μL of target fluid for cornulin).
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Table 12: Sensitivity Limits for Individual Biological Matrices.
1

2

4

8

16

32

64

128

256

Dilution Factor
512
1,024

2,048

4,096

8,192

16,384

32,768

65,536

131,072

262,144
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Alpha 1 Antitrypsin LSITGTYDLK
SVLGQLGITK
Hemopexin
NFPSPVDAAFR
GGYTLVSGYPK
Hemoglobin
SAVTALWGK
GTFATLSELHCDK
Menstrual Fluid
Cornulin
GQNRPGVQTQGQATGSAWVSSYDR
ISPQIQLSGQTEQTQK
LY6
GCVQDEFCTR
DGVTGPGFTLSGSCCQGSR
NGAL
WYVVGLAGNAILR
SYPGLTSYLVR
Suprabasin
ALDGINSGITHAGR
Cornulin
GQNRPGVQTQGQATGSAWVSSYDR
ISPQIQLSGQTEQTQK
LY6
GCVQDEFCTR
Vaginal Fluid
DGVTGPGFTLSGSCCQGSR
NGAL
WYVVGLAGNAILR
SYPGLTSYLVR
Suprabasin
ALDGINSGITHAGR
Alpha 1 Antitrypsin LSITGTYDLK
SVLGQLGITK
Hemopexin
NFPSPVDAAFR
Peripheral Blood
GGYTLVSGYPK
Hemoglobin
SAVTALWGK
GTFATLSELHCDK
Statherin
FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF
SubMax
GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR
Saliva
IPPPPPAPYGPGIFPPPPPQP
Amylase
LSGLLDLALGK
IAEYMNHLIDIGVAGFR
PAP
FQELESETLK
ELSELSLLSLYGIHK
PSA
IVGGWECEK
Seminal Fluid
LSEPAELTDAVK
Semenogelin 2 DIFTTQDELLVYNK
DVSQSSISFQIEK
Uromodulin
TLDEYWR
Urine
STEYGEGYACDTDLR

Note: Peptides that were identified in the majority of prep replicates are shown in dark green. Red indicates where a paired
peptide for a target protein dropped out prior to the secondary peptide target for the protein. White indicates the failure to detect
a given peptide in the majority or all of prep replicates.
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3.2.3.4 Repeatability and Reproducibility

To assess repeatability and reproducibility, equal-volume samples of a single body
fluid from 10 human subjects were pooled. From these stocks, a total of 18 replicates for
each fluid were prepared such that two separate analysts could extract and analyze three
samples from each fluid per day over a period of three days.

Sample extraction

repeatability and reproducibility was assessed by evaluating the variation in calculated
average BCA protein quantitative values. The calculated percent coefficient of variation
(%CV) values for each body fluid are indicated in Tables 13-18. All targets fell within the
maximum allowable %CV of 25%, which is a common industry benchmark for extraction
repeatability and reproducibility. The only exception to this was associated with the urine
targets where greater sample-to-sample variation was expected here to the additional
precipitation step that was included in the sample preparation protocol to reduce the
negative impact of urea on the samples assay.
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Table 13. Extraction Reproducibility for
Peripheral Blood

Table 14. Extraction Reproducibility for
Urine (Precipitated)

Table 15. Extraction Reproducibility for
Saliva

Table 16. Extraction Reproducibility for
Seminal Fluid
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Table 17. Extraction Reproducibility
for Vaginal Fluid

Table 18. Extraction Reproducibility for
Menstrual Fluid
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The %CV values for each body fluid for the overall analytical method was assessed
by evaluating the variation in normalized peak area (response ratio of tryptic peptide
compared to labeled internal standard) and retention times (Table 19). As was observed
with the measured repeatability and reproducibility of the extraction protocol, the majority
of overall analytical method repeatability and reproducibility were within maximum
allowable ranges, with the notable exception of urine. Elevated peak area %CV values for
hemoglobin peptides (SAVTALWGK and GTFATLSELHCDK) and semenogelin-II
peptide (DIFTTQDELLVYNK) were present in high abundance leading to suboptimal
peak morphology and integration with high protein input samples. As a result, greater
%CVs were observed for the area ratios of “natural” and “heavy” labeled peptides. This
was readily ameliorated through sample dilution. Conversely, the ALDGINSGITHAGR
peptide for suprabasin exhibited elevated peak area %CV values for natural ion response
ratios as this peptide was present at low quantities which approached the lower limit of
detection. The difficulty of detection at the lower limit of the assay unavoidably leads to
greater %CV as it does with any other analytical assays.
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Table 19. Repeatability (Analyst 1 and 2) and Reproducibility (Overall) of the Analytical
Method

LSITGTYDLK
SVLGQLGITK
NFPSPVDAAFR
Hemopexin
GGYTLVSGYPK
SAVTALWGK
Hemoglobin
Menstrual Fluid
GTFATLSELHCDK
ISPQIQLSGQTEQTQK
Cornulin
GCVQDEFCTR
LY6
WYVVGLAGNAILR
NGAL
SYPGLTSYLVR
ALDGINSGITHAGR
Suprabasin
LSITGTYDLK
Alpha 1 Antitrypsin
SVLGQLGITK
NFPSPVDAAFR
Hemopexin
Peripheral Blood
GGYTLVSGYPK
SAVTALWGK
Hemoglobin
GTFATLSELHCDK
GQNRPGVQTQGQATGSAWVSSYDR
Cornulin
ISPQIQLSGQTEQTQK
GCVQDEFCTR
LY6
Vaginal Fluid
WYVVGLAGNAILR
NGAL
SYPGLTSYLVR
ALDGINSGITHAGR
Suprabasin
FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF
Statherin
GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR
SubMax
Saliva
IPPPPPAPYGPGIFPPPPPQP
LSGLLDLALGK
Amylase
IAEYMNHLIDIGVAGFR
ELSELSLLSLYGIHK
PAP
IVGGWECEK
PSA
Seminal Fluid
LSEPAELTDAVK
DIFTTQDELLVYNK
Semenogelin 2
DVSQSSISFQIEK
TLDEYWR
Uromodulin
Urine
STEYGEGYACDTDLR
Alpha 1 Antitrypsin

Normalized Peak Area
Analyst 1 Analyst 2 Overall
%CV
%CV
%CV
8.30
7.70
8.30
8.30
5.70
10.10
8.40
7.90
3.00
21.80
20.45
23.50
7.20
4.20
3.30
34.60
39.90
28.90
21.30
20.80
21.98
13.00
12.50
13.50
26.70
24.40
26.50
7.10
6.80
7.00
25.70
21.08
28.60
16.70
17.30
16.40
16.10
17.20
15.30
11.80
10.70
13.10
9.70
8.80
10.50
39.90
27.10
16.20
39.40
23.20
44..2
89.60
3.20
7.80
7.40
7.50
7.40
8.50
3.50
7.50
5.30
4.30
6.20
3.70
3.00
4.30
12.60
12.10
12.20
5.60
5.00
6.10
3.40
2.60
3.70
7.10
7.50
6.70
7.20
7.80
6.80
8.00
6.70
3.10
22.70
20.20
25.40
20.70
17.30
24.10
18.60
16.30
21.10
32.70
31.30
34.50
21.50
18.70
24.30
46.50
45.30
16.90
79.10
81.80
63.80

Retention Time
Analyst 1 Analyst 2 Overall
%CV
%CV
%CV
0.50
0.38
0.61
0.43
0.39
0.48
0.71
0.61
0.79
0.76
0.59
0.88
0.64
0.45
0.80
1.14
0.87
1.37
0.68
0.51
0.82
0.73
0.44
0.90
0.33
0.28
0.33
0.43
0.36
0.49
0.86
0.55
1.09
0.78
0.94
0.59
0.83
0.62
1.00
0.94
0.79
1.08
0.95
0.95
0.90
1.01
1.12
0.88
1.00
1.68
0.79
0.75
0.49
0.94
0.53
0.43
0.59
1.07
0.44
1.45
0.23
0.23
0.24
0.75
0.88
0.62
0.82
0.54
1.04
0.16
0.13
0.19
0.22
0.18
0.25
0.46
0.48
0.36
0.30
0.32
0.28
0.24
0.23
0.25
0.22
0.22
0.21
1.31
1.15
1.37
0.47
0.34
0.54
0.34
0.32
0.35
0.49
0.38
0.55
1.23
1.02
1.37
1.06
0.97
1.15

3.2.3.5 Species Specificity

Both in silico and empirical methods were used to assess assay species specificity.
The amino acid sequences of all target peptides were screened against the SWISS-PROT
database containing 550,116 district proteins from 13,257 species.
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Additionally,

conceptual amino acid translations of all DNA sequences in GenBank and NCBI RefSeq
were searched using the PSI-BLAST algorithm to search for position specific matches.
Results of these database searches are provided in Tables 20-24. There is some shared
homology with higher order primates as expected given the close evolutionary relatedness
of these species to modern humans. Overall, however, there are a subset of select peptides
for each fluid that are human-specific with no know shared expression in non-human
primates. This fact has been taken into consideration in the design of interpretation
guidelines generated for this multiplex assay.
Table 20: Species Specificity of Urine Biomarker Peptides Based on in silico Searches

Table 21. Species Specificity of Seminal Fluid Biomarker Peptides based on in silico
Searches
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Table 22. Species Specificity of Saliva Biomarker Peptides Based on in silico Searches

Table 23. Species Specificity of Vaginal/Menstrual Fluid Biomarker Peptides Based on in
silico Searches

Table 24. Species Specificity of Peripheral Blood Biomarker Peptides Based on in silico
Searches
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While in silico database searches represent a near exhaustive approach to assessing
species specificity, additional non-human samples were tested to empirically demonstrate
the human specificity of target biomarker peptides in this panel. As hemoglobin is the
target biomarker that is most widely conserved across non-human mammalian species,
blood samples from a variety of mammals including domestic pets (dogs and cats) and
species commonly hunted in the US (bear, turkey, deer, and coyote) were tested. No peaks
corresponding to human proteins were detected in any tested samples (Table 25 and
Figure 22).

Peripheral
Blood

Table 25. Species Specificity of Peripheral Blood Biomarker Peptides based on empirical
testing using the QQQ-MRM Assay and non-human blood.
Alpha 1 LSITGTYDLK
Antitrypsin SVLGQLGITK
NFPSPVDAAFR
Hemopexin
GGYTLVSGYPK
SAVTALWGK
Hemoglobin
GTFATLSELHCDK

Dog 1
ND
ND
ND
ND
ND
ND

Dog 2
ND
ND
ND
ND
ND
ND

Cat 1
ND
ND
ND
ND
ND
ND

Cat 2
ND
ND
ND
ND
ND
ND

Deer 1
ND
ND
ND
ND
ND
ND

Deer 2
ND
ND
ND
ND
ND
ND

Bear 1
ND
ND
ND
ND
ND
ND

Bear 2
ND
ND
ND
ND
ND
ND

Otter
ND
ND
ND
ND
ND
ND

Turkey
ND
ND
ND
ND
ND
ND

Coyote
ND
ND
ND
ND
ND
ND

Figure 22. Results from the myelin basic protein internal positive control used with the
non-human blood samples. Successful digestion of extracted proteins is indicated by the
presence of digested myelin basic protein (red) and corresponding AQUA peptide standard
(blue).
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3.2.3.6 Mixture Study
Mixtures prepared at a 1:1 ratio (25 μL total volume) were generated in triplicate
for all possible pairings of the six targeted biological fluids. In total, 45 mixed samples
were tested. As previously indicated, successful identification of a biological fluid required
the unambiguous identification of one or more protein biomarker targets. In 42 of the 45
samples tested in this study, the assay accurately characterized the fluids present in the
mixture and did not detect any additional targets that were not present (i.e., no false positive
results were obtained) (Tables 26-31). In the remaining three mixture samples, the assay
failed to identify uromodulin when mixed with semen, menstrual fluid or peripheral blood
(Table 31). As described under the sensitivity section of this paper, the assay’s sensitivity
for the detection of uromodulin was the lowest (i.e., the least sensitive) of all markers
targeted by the assay while semen and blood (menstrual and peripheral) contain the
biomarker peptides found in greatest abundance. Since mixed body fluid samples were
analyzed on the basis of the total protein concentration of the initial extract, the inability to
detect the body fluid with a low amount of protein when mixed with a body fluid of high
protein content is not necessarily unexpected. This is at least in part due to dilution of lower
abundance protein target as well as potential ion suppression by the high-abundance protein
biomarker.
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Saliva

Semen

Urine

Peripheral
Blood

Vaginal Fluid

Menstrual Fluid

Table 26. Peripheral Blood Detection in Mixed Body Fluids

YES

YES

YES

YES

Alpha
1
Antitrypsin
Hemopexin
Hemoglobin

Sufficient Peripheral Blood
YES
Markers for Identification

Peripheral Blood

Vaginal Fluid

Seminal Fluid

ND

ND

ND

ND

Sufficient Saliva Markers for
YES
Identification

YES

YES

YES

Statherin
Saliva

Urine

Menstrual Fluid

Table 27. Saliva Detection in Mixed Body Fluids

SubMax
Amylase
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YES

Menstrual Fluid

Peripheral Blood

Vaginal Fluid

Saliva

Urine

Table 28. Seminal Fluid Detection in Mixed Body Fluids

Sufficient Semen Markers for
YES
Identification

YES

YES

YES

YES

PAP
Semen

PSA
Semenogelin 2

Cornulin
LY6

Urine

Semen

Saliva

Peripheral Blood

Menstrual Fluid

Table 29. Vaginal Fluid Detection in Mixed Body Fluids

ND
ND

Vaginal Fluid
NGAL
Suprabasin
Sufficient Vaginal Fluid Markers
YES
for Identification

ND
YES
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ND

YES

YES

YES

Saliva

Semen

ND

ND

ND

YES

YES

YES

Urine

Vaginal Fluid

Peripheral Blood

Table 30. Menstrual Fluid Detection in Mixed Body Fluids

Alpha
1
Antitrypsin
Hemopexin
Menstrual
Fluid

Hemoglobin
Cornulin
LY6
NGAL

ND

Suprabasin
Sufficient Menstrual Fluid
YES
Markers for Identification

YES

Sufficient Urine Markers for
NO
Identification

NO
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Semen

ND

Uromodulin

Saliva

Peripheral Blood

ND

Urine

Vaginal Fluid

Menstrual Fluid

Table 31. Urine Detection in Mixed Body Fluids

ND
YES

YES

NO

3.2.3.7 Casework Samples

Simulated casework samples were prepared to assess performance of the
multiplexed body fluid identification assay over a broad range of sample conditions. Over
100 samples were prepared which included single-source body fluids, mixed body fluids
and sexual assault type stains recovered from a variety of substrates (e.g., cotton, denim,
leather, synthetic fibers, latex and glass).

The potential impact of environmental

contaminants and potential inhibitory substance (e.g., spermicides, personal lubricants,
detergent, soil, acids, leather, indigo dye, bleach and tobacco juice) were assessed. To
explore the impact of degradation, samples were subjected to a variety of environmental
insults (e.g., aging and known proteolytic enzymes). All casework-type samples were
prepared and tested in triplicate.
As shown in Table 32, MRM analysis was able to unambiguously identify
individual protein components for almost all simulated casework samples. However,
mixing neat laundry detergent or 10% bleach with samples resulted in a failure to detect
any blood-specific proteins. As is the case with genetic analysis, the development of
additional front-end sample preparation protocols may enable successful processing of
these samples (Figure 23).
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Table 32. QQQ-MRM Detection of Body Fluid Biomarkers in Forensic Casework-Type
Fl ui d Confi rma ti on
Samples.

Urine Case Samples

Semen Case Samples

Saliva Case Samples

Peripheral Blood

Menstrual Blood

Vaginal Fluid
Case Samples

Va gi na l
Fl ui d

Peri phera l
Bl ood

Sa l i va

Semen

Uri ne

10 µL on Cotton

ND

ND

ND

ND

Fi nger Swa b

ND

ND

ND

ND

Peni l e Swa b

ND

ND

ND

ND

10 µL on Cotton

ND

ND

ND

10 µL on Deni m

ND

ND

ND

10 µL on Pa d

ND

ND

ND

5 µL on Recta l Swa b

ND

ND

ND

50 µL Dri ed on Spermi ci de Condom
col l ected wi th 2% SDS s wa b

ND

ND

ND

5 µL pl us 5 µL Lubri ca nt Dri ed on Swa b

ND

ND

ND

10 µL on Swa b Conta i ni ng Soi l

ND

ND

ND

ND

10 µL on Swa b wi th 10 µL 10% Bl ea ch

ND

ND

ND

ND

10 µL on Lea ther

ND

ND

ND

ND

10 µL on s wa b pl us 50 µL Detergent

ND

ND

ND

ND

10 µL on Deni m

ND

ND

ND

ND

10 µL on Cotton

ND

ND

ND

ND

Gum

ND

ND

ND

ND

50 µL dri ed on Gl a s s Bottl e
col l ected wi th 2% SDS s wa b

ND

ND

ND

ND

10 µL on Cotton

ND

ND

ND

ND

10 µL on Condom
col l ected wi th 2% SDS s wa b

ND

ND

ND

ND

10 µL Chewi ng Toba cco Spi t Dri ed on Swa b

ND

ND

ND

ND

50 µL dri ed on Condom
col l ected wi th 2% SDS s wa b

ND

ND

ND

ND

10 µL on Cotton

ND

ND

ND

ND

10 µL on Deni m

ND

ND

ND

ND

10 µL on Ora l Swa b

ND

ND

ND

ND

10 µL on Recta l Swa b

ND

ND

ND

ND

50 µL dri ed on Spermi ci de Condom
col l ected wi th 2% SDS s wa b

ND

ND

ND

ND

5 µL wi th 5 µL Lubri ca nt on Swa b

ND

ND

ND

ND

10 µL on Cotton

ND

ND

ND

ND

10 µL pl us 50 µL Soda on Swa b

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

100 µL Dri ed on Cera mi c Cup
col l eted wi th 2% SDS s wa b
100 µL Dri ed on Styrofoa m Cup
col l eted wi th 2% SDS s wa b

Note: Dark Green indicates all peptide targets were present. Light green indicates at least
1 target peptide was present and at least 1 target peptide was not detected. Red indicates
no target peptides were detected.
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Figure 23: Results obtained for the myelin basic protein internal positive control. Target
peptides representing bovine myelin basic protein were undetectable in this sample
consisting of peripheral blood mixed with detergent. This indicates that the digestion of
peripheral blood proteins that is required to produce the target peptides had failed.

Given the frequency with which partially degraded samples are encountered by
forensic practitioners, protein degradation was also evaluated. The results obtained were
consistent with those expected, given the published literature which supports the greater
stability of proteins over time as compared to nucleic acids. A series of saliva, peripheral
blood, semen and urine samples which had been aged at room temperature from 2 to 7
years were analyzed. As illustrated in Tables 33-36, the MRM assay provided for the
confident identification of all body fluids based on the presence of at least one and often
multiple target biomarkers in all aged samples tested.
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Table 33. QQQ-MRM Detection of Peripheral Blood Biomarkers Aged Bloodstains
Blood
7 years 5 years 4 years 2 years 2 years

Peripheral
Blood

Biomarkers

Alpha 1 Antitrypsin
Hemopexin
Hemoglobin

Table 34. QQQ-MRM Detection of Saliva Biomarkers Aged Stains

Saliva

Saliva

Biomarkers

Statherin
SubMax
Amylase

3 Years 3 Years 3 Years
ND
ND
ND
ND

Table 35. QQQ-MRM Detection of Seminal Fluid Biomarkers Aged Stains
Semen

Semen

Biomarkers

Acid Phosphatase
Prostate Specific Antigen
Semenogelin 2

5 years 5 years 4 years 4 years 2 years 2 years 2 years
ND
ND
ND
ND
ND
ND
ND
ND
ND

Table 36. QQQ-MRM Detection of Urine Biomarkers Aged Stains

Urine
3 years 3 years 3 years

Urine

Biomarkers

Uromodulin
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3.3 Discussion

Highly tissue-specific target protein biomarkers for biological fluids of forensic
interest – namely peripheral blood, semen, saliva, urine, and vaginal/menstrual fluids have
been identified. Additionally, the assay targeting these markers has undergone extensive
developmental validation including an assessment of aged samples, environmental impact,
species specificity, stability, sensitivity, reproducibility/repeatability, and mixture analysis.
Overall, it has been demonstrated that a multiplex targeted ion mass spectrometry-based
assay allows for the serological identification of body fluids most commonly encountered
in forensic casework. With sufficient gains in sensitivity and specificity, serological
identification utilizing protein mass spectrometry analysis offers significant advantages
compared to the existing immunological and biochemical tests currently employed by
forensic serologists.
The deliverable to the forensic community following the research presented in this
chapter includes a functional and developmentally-validated multiplex human body fluid
identification assay. This assay has the potential to significantly improve the accuracy and
sensitivity of serological testing of forensically relevant biological fluids. While the
multiplex design of this assay eliminates the need to perform separate tests on an unknown
stain, however, it requires longer analytical run times and may be unnecessarily
comprehensive for routine screening of targeted forensic workflows. The analysis of items
of items of evidence from sexual assault kits for example are typically only screened for
semen (and possibly saliva). The creation of a targeted assay for this specific purpose
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would allow for faster analytical run times and greater sensitivity for fluids relevant to
targeted workflows.
The remaining two chapters of this dissertation will therefore focus on the
application of a QQQ-MRM assay that has been optimized for analysis of sexual assault
kit evidence capable of detecting seminal fluid markers.

This approach would enable

forensic analysts to obtain a confirmatory identification of semen in extended post-coital
samples. This approach would also allow for the confirmation of semen in samples where
there was insufficient DNA to obtain an interpretable profile (e.g., vasectomy, lack of
ejaculation or minimal sexual contact). In short, the conversion of this multiplex assay to
a fit-for-purpose monoplex assay for the analysis of sexual assault kit evidence would make
it possible to obtain probative results from samples that might otherwise have yielded
inconclusive or no results at all, providing the forensic and criminal justice communities
with a powerful tool to aid the investigation and prosecution of sexual assault.
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CHAPTER 4: IMPROVING SEMINAL FLUID DETECTION SENSITIVITY IN
EXTENDED POST-COITAL INTERVALS BY QQQ MASS SPECTROMETRY

4. Introduction

In 2017, the FBI Crime Statistics reveled that an estimated 135,755 rapes were
reported to US law enforcement agencies [91]. After several consecutive years of increases,
the overall number of violent crimes reported according to the FBI figures decreased in
2017, however, the number of reported aggravated assaults and rapes continued to increase
by 1.0 and 2.5 percent respectively over 2016 numbers. Approximately 18% of women in
the US have been raped in their lifetime [92]. This includes an estimated 1.8 million
adolescent victims [93]. While the timely recovery of physical evidence is critical to sexual
assault investigations, many sexual assault victims delay reporting the incident to
authorities for three to four days after an attack. This is especially true of child victims,
where disclosure of sexual abuse and rape may be delayed even longer [76].
The timely recovery of physical evidence of a potential sexual assault is vital. As
the post-coital interval is extended, the potential for successful identification of probative
evidence such as seminal fluid and/or DNA diminishes rapidly. For this reason, the length
of time after a sexual assault (i.e., the post-coital interval) can influence the potential for
subsequent forensic testing to yield probative results; the priority assigned to testing a
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sexual assault evidence kit (especially in the case of backlog reduction efforts); and even
the decision of whether or not an effort to collect physical evidence of sexual assault will
be made at all.
In sexual assault cases, the detection of seminal markers in the vagina or cervix
constitutes important physical evidence of sexual contact. Accordingly, numerous studies
have evaluated the persistence of semen in the post-coital interval. Semen, in these studies,
is usually identified by the presence of spermatozoa although the persistence of
biochemical markers of seminal fluid (e.g., choline, acid phosphatase, PSA/p30 and
semenogelin) have also been investigated. Difficulty in detecting seminal fluid markers,
sperm and/or DNA past a post-coital interval of 5-7 days, however, has been widely
reported in the literature [94, 95]. Aside from vasectomized and azoospermic males, semen
loss due to vaginal lavage, drainage and degradation can all impede the ability to detect
spermatozoa and/or obtain interpretable DNA typing results. Similarly, these factors limit
the ability to detect evidence of sexual contact through the use of serological assays that
indicate the potential presence of seminal fluid.
There are widely varying estimates of how long into the post-coital interval the
cellular and biochemical components of semen can be detected. The literature on sperm
detection in the vagina and cervix exemplifies this. Estimates of the time period within
which sperm can be recovered from the vaginal cavity of healthy females range from 30
minutes to 19 days post coitus [96-105]. The majority of authors, however, report finding
spermatozoa up to 3 days post coitus in the vagina and up to 7 days post coitus in the cervix.
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Most reports suggesting a 17-19 day post-coital interval for sperm recovery cite two articles
published in 1891 and 1977; both of which relied on volunteer self-reporting of findings
that were regarded as “possibly correct” [106].
Serological detection of seminal fluid is typically based on antibody-antigen
interactions (i.e., immunochromatography). PSA/p30 or semenogelin are commonly used
as the target protein biomarkers. Validation studies using commercial assays suggest that
spermatozoa persist longer than seminal fluid protein markers. In one study, post-coital
vaginal swabs failed to produce positive results for semenogelin or PSA just 3 and 33 hours
after intercourse, respectively [81]. Even when nylon flocked swabs were used to maximize
sample release, semenogelin and PSA/p30 were reliably detected only up to 12 hours postcoitus. In rare cases, positive results were obtained up to 60 hours after intercourse. What
is important, however, is that in 50% of samples that were negative for semenogelin and
PSA, partial male DNA profiles were still generated [107].
The ability to generate interpretable male DNA profiles at various post-coital
intervals has also been widely investigated. While DNA profiling can help to establish the
identity of a male contributor, sexual assault samples often contain an excess of epithelial
cells from a female victim. This can hinder, or entirely preclude, the detection of the male
fraction of a mixture when autosomal STRs are used [108]. In such cases, amplification
of male-targeted Y-STR loci is used. Though Y-STR haplotyping allows for the selective
isolation of a male profile, the results have a much lower power of discrimination than
profiling using autosomal markers. In general, however, complete Y-STR haplotypes can
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be obtained from vaginal/cervical swabs up to approximately 3-4 days post coitus. After
that, partial profiles continue to be detected up to approximately 5-6 days post-coitus [109111].
The apparent rapid loss of protein indicators of seminal fluid is somewhat
unexpected given that proteins typically remain stable under conditions that lead to the
degradation of other biomolecules. In fact, as previously mentioned proteins are among
the most long-lasting of all biological molecules having been routinely isolated from even
ancient biological material [72, 112]. In a forensically applicable study, protein levels
remained relatively constant even in post-mortem brain tissue [73]. This suggests that the
difficulty of detecting seminal fluid proteins in the post-coital interval may be due more to
the sensitivity limits of conventional immunochromatographic assay systems than to the
loss of the actual target proteins. Antibody-based tests are also subject to both false positive
and false negative results – the former being due either to the presence of the target seminal
fluid antigen in non-target body fluids (e.g., female ejaculate [14], breast milk [16], and
urine [17])(i.e., a true positive for the target biomarker but a false indication of seminal
fluid) or non-specific binding events such as those triggered by organic acids as indicated
in chapter 2 (i.e., a true false positive result). Even when successful, however, these tests
provide only a presumptive indication that seminal fluid may be present.
A more sensitive and specific technology for the confirmatory identification of
seminal fluid – one that could match the sensitivity of DNA testing methodologies or even
identify seminal plasma in vaginal fluid several days after an alleged sexual assault in cases
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where there is insufficient DNA to obtain an interpretable profile – would provide critical
physical evidence of sexual contact. With improved sensitivity, forensic examiners would
have the potential to extend the post-coital interval for sample collection with an improved
likelihood of successfully obtaining an interpretable DNA profile.
Selected reaction monitoring (SRM) has a long history of use in the fields of
toxicology and pharmacokinetics [113]. SRM allows for the specific monitoring of a
targeted analyte in a complex mixture. Typically, a triple quadrupole-based mass
spectrometer is employed to achieve this. The first mass analyzing quadrupole of the triple
quadrupole system allows for the selective passage of a target parent ion by specifying a
narrow mass window. This parent ion is then fragmented in the second quadrupole, while
the third quadrupole scans for a desired fragment ion. The identification of both a parent
and fragment ion (i.e., a transition) provides for high-confidence peptide identification. In
contrast to SRM strategies, Multiple Reaction Monitoring (MRM) approaches scan for
several different parent and multiple fragment ions within one run. MRM allows for greater
productivity over SRM but generally this is achieved at the cost of sensitivity [114]. As
the number of transitions monitored per assay increases, the dwell time (i.e., the time the
instrument takes to cycle through the separation and detection of each transition) for each
targeted ion decreases. Therefore, the more ions targeted, the less time the instrument
spends detecting and measuring any one ion. This leads unavoidably to an overall decrease
in sensitivity.
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A well-established technology for the unambiguous detection of proteins in
complex biological fluids is triple quadrupole mass spectrometry utilizing multiple reaction
monitoring (QQQ-MRM). These studies outlined in this chapter have applied a QQQMRM approach to the detection of seminal fluid in cervico-vaginal swabs collected at
extended post-coital intervals of ≥5 days). The results of this testing were compared to
existing antibody-based methods to assess the relative utility of a QQQ-MRM approach in
the analysis of sexual assault samples.
Narrowing the scope of the multiplex body fluid proteomic assay detailed in
Chapter 3, the creation of a seminal fluid-specific monoplex assay is expected to enhance
the sensitivity of the method beyond what has been achieved to date.

Moreover, the

enhanced sensitivity should allow for the detection of seminal fluid protein markers in
samples

well

past

the

post-coital

interval

that

is

attainable

with

the

immunochromatographic assays currently used by forensic labs. The research outlined in
this chapter therefore aims to:
(1) Develop and optimize a monoplex QQQ-MRM assay for seminal fluid using
single- and mixed-stain swabs that are representative of sexual assault samples.
(2) Rigorously assess the extended post-coital time limit for which seminal fluid
biomarkers can be confirmed in sexual assault type samples.
The successful completion of these aims will facilitate the analysis of challenging sexual
assault evidence and extend the critical widow within which sexual assault kits can be used
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to collect samples from the victim with a reliable expectation of obtaining probative test
results.

4.1 Methods

4.1.1 Chemicals and Reagents

Dithiothreitol (DTT), and Iodoacetamide (IAA), and 2,2,2-Trifluoroethanol (TFE)
were purchased from Sigma-Aldrich (St. Louis, MO). Mass Spec grade Trypsin gold was
sourced from Promega (Madison, WI). LCMS grade water acetonitrile, methanol, and
acetone were purchased from Honeywell/Burdick and Jackson (Muskegon, Michigan). All
sample preparation was carried out in Eppendorf LoBind Protein microcentrifuge tubes.
Absolute Quantification (AQUA) C-terminus labelled peptides were custom synthesized
by New England Peptide (Gardner, MA) and delivered as lyophilized 2 nmol aliquots.
Intact myelin basic and aprotinin stock solutions (1 mg/mL) were purchased from New
England Peptide (Gardner, MA) for use as internal positive controls.

4.1.2 Body Fluid Collection

Body fluids were collected in accordance with procedures approved by the
University of Denver’s Institutional Review Board for Research Involving Human Subjects
as previously described in Chapter 3. Following collection and processing, all samples
(peripheral blood, menstrual blood, vaginal secretions, semen, urine and saliva) were
aliquoted into 1.5mL microcentrifuge tubes and stored at -80ºC. In general, and unless
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otherwise indicated, 50 µl of blood or 125 µl of all other biological matrices were used for
the identification of target protein biomarkers.

4.1.3 LC-MS/MS Analysis
Optimal parent-fragment ion pairs for high-specificity biomarkers had already been
identified for semen, saliva, urine, peripheral blood and vaginal/menstrual fluid as
described previously in Chapter 3. In the original multiplex assay, up to three proteins/fluid
were selected. Generally, two to three optimal peptides were selected (as parent ions) for
each protein. Similarly, two to three fragment ions were selected per parent ion. This
redundancy allowed for greater productivity and selectivity in the multiplex assays. As
mentioned previously, however, this comes at the cost of sensitivity when using SRM
assays.
The primary objective of the work described in this chapter, therefore, was to
develop and optimize a monoplex QQQ-MRM assay for seminal fluid. This was achieved
by importing the existing multiplex method but eliminating all biomarker peptides not
specific to seminal fluid. What remained were the parent-fragment ion pairs for prostatic
acid phosphatase, prostate specific antigen and semenogelin. Iterations of this method were
developed in which parent and fragment ion pairs were sequentially eliminated until an
SRM method with one peptide for each seminal fluid protein biomarker with one fragment
remained. This was done with the objective of maximizing the dwell time efficiency of the
instrument; thereby maximizing detection sensitivity. Each of the resulting monoplex assay
methods was assessed for sensitivity by analyzing vaginal swabs spiked with known
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quantities of semen. Neat pooled seminal fluid from 10 male donors was diluted at the
following ratios: 1:800, 1:4,000, and 1:20,000 and digested. After digestion, 125µL
aliquots were lyophilized and reconstituted for analysis by LC-MS/MS. Each sample was
analyzed under each of the iterations of the seminal fluid assay.
Assay specificity was also assessed by analyzing a series of 25 replicate two-, threeand four-component mixtures consisting of saliva, semen, vaginal secretions, urine,
peripheral and/or menstrual blood. The method found to be the most specific for seminal
fluid with the greatest sensitivity was used for the remainder of the study.
The second part of the optimization process was to evaluate injection quantity. With
a multiplex assay, it is difficult to establish a set injection quantity, given the greatly varied
amounts of targeted protein per matrix. For example, the amount of hemoglobin in a given
volume of blood is not comparable to the amount of submaxillary gland androgenregulated protein 3B in the same volume of saliva. With one matrix and one sample type
from sexual assault kits (vaginal, oral and rectal swabs), it is easier to evaluate how much
protein can be injected without overloading the column. Neat semen (25µL) was added to
pooled vaginal secretions and quantified for total protein content. The following amounts
of total protein were targeted for digestion: 50 µg, 75 µg, 100 µg, 150 µg and 200 µg.
These amounts were loaded onto 96-well plates for digestion and sample clean-up which
was performed on the AssayMAP Bravo Platform. All samples were reconstituted in 2%
acetonitrile/0.1% formic acid solution to a 1µg/µL concentration and a 10µL aliquot was
injected on the column.
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4.1.4 Post-Coital Interval Assessment
The second objective of the research reported in this chapter was to determine the
extent to which an optimized monoplex QQQ-MRM assay for semen could be used to
extend the post-coital interval within which the presence of seminal fluid can be reliably
detected in cervico-vaginal samples. Typically, these studies employ a self-collection
swabbing method at various time points after sexual intercourse. However, this introduces
a great amount of variability into the data set thereby compromising the precision of results
both amongst and within the sample sets for the individuals participating in the study.
As it has already been documented in the literature (at least for spermatozoa) that
seminal persistence is greater at the cervix, this study used cervical swabs obtained by a
trained sexual assault nurse examiner and collected with a speculum to better represent
samples that would be generated as part of an authentic sexual assault examination. Two
swabs at a time were collected from female volunteers after separate acts of sexual
intercourse at multiple time points (2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days,
and 9 days) using sterile nylon flocked applicators. In order to eliminate variability due to
the combined effect of multiple acts of intercourse, volunteers were asked to abstain from
intercourse for 12 days prior to the sexual act that was to be followed by sample collection.
In order to prevent loss of seminal fluid markers from the sampling process itself, only one
set of swabs was collected after each act of sexual intercourse. All swabs were air dried,
packaged in sterile paper envelopes and stored at -20°C until extracted for analysis. At least
two separate collections per post-coital time interval were assessed.
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4.2 Results

4.2.1 Development of the Monoplex QQQ-MRM Assay for Seminal Fluid

The existing six-body fluid multiplex assay was imported and all biomarker
peptides that were not specific to seminal fluid were eliminated. What remained were
parent-fragment ion pairs for prostatic acid phosphatase, prostate specific antigen and
semenogelin I and II. Iterations of this method were developed in which parent and
fragment ion pairs were sequentially eliminated in order to maximize the dwell time
efficiency of the instrument; thereby maximizing detection sensitivity while maintaining
assay specificity. Additional biomarkers, not part of the original six-body fluid multiplex
assay, were also incorporated into the methods to further optimize the specificity and
sensitivity. These markers, many of which were high quality target biomarkers, had
originally been eliminated due to the fact that they generated assay interference because
they coeluted with protein biomarker targets from other biological fluids that the assay was
looking for at approximately the same retention time. Since the detection of these other
body fluids was no longer part of the seminal fluid assay, the concerns associated with
coeluting species were eliminated and the potential utility of these biomarker targets could
be reevaluated. Targets incorporated into the various iterations of the monoplex seminal
fluid assay as well as their respective specificities can be found in Table 37.

108

Table 37. Peptide Targets Evaluated for the Development of the Monplex QQQ-MRM
Seminal Fluid Assay.

Note: Those peptides abbreviated with a “*” were not part of the original 6 fluid multiplex
assay and reincorporated for evaluation with the seminal fluid assays.

The most abundant peptides per protein were selected based on preliminary
qualitative studies. A scheduled and unscheduled method incorporating all target peptides
identified in Table 37 was first compared. A scheduled method utilizes retention time
windows in order to target specific transitions at a precise retention time. This is an
alternate strategy for decreasing dwell time (Figure 24). Four additional paired down
scheduled methods were also assessed.

109

Figure 24. Scheduled (bottom) versus unscheduled (top) methods of analysis on an LCMS/MS. During an unscheduled method, the instrument filters and scans for all targets
throughout the entirety of the run. During a scheduled method, detection windows are set
based on retention times for each fragment, allowing the instrument to scan and filter for
those target analytes only during specified periods of time during the run, decreasing dwell
time of the method and therefore increasing overall sensitivity.

When comparing results from the unscheduled and scheduled methods, significant
improvements in sensitivity were observed with the scheduled method (Figure 25). An
ANOVA with a 95% confidence interval was performed on normalized peak areas for each
peptide across all 6 methods evaluated (1 unscheduled and 5 scheduled) to determine
statistical significance. Significant differences between methods were observed for all but
the FQEL peptide of the prostatic acid phosphatase protein (ELSE: Fs=33.833; df=2,6;
P=5.40e-4, IVGG: Fs=28.338; df=2,6; P=8.77e-4, LSEP: Fs=23.207, df=4,10; P=4.79e-5,
DIFS: Fs=9.625; df=5,12; P=0.0007, LPSE: Fs=51.291; df=3,8; P=1.438e-5, DVSQ:
Fs=6.736; df=5,12; P=0.0032, DIFT: Fs=5.693; df=3,8; P=0.0219; FQEL: Fs=2.947;
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df=1,4; P=0.1611). A post-hoc Tukey test with a 95% confidence interval showed that all
scheduled methods evaluated produced significantly greater peak areas and intensities for
all peptides as compared to the unscheduled method while no statistical differences of mean
peak areas were observed between any scheduled methods assessed in which parent and
fragment ion pairs were eliminated with the exception of the LPSE peptide for SgI
(Appendix II). Given that scheduled methods were employed and that there was no
coelution of targets in the method, this was an expected outcome.

Figure 25. Chromatographic comparison of the unscheduled and scheduled methods for
the Semenogelin II peptide DVSQ. The peak intensities are labeled in the upper right hand
corner of each chromatogram.
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Assay specificity was assessed by analyzing a series of at least 25 replicate two-,
three- and four-component mixtures consisting of saliva, semen, urine, peripheral blood
and vaginal/menstrual fluids (Figure 26). Since no significant difference in sensitivity was
observed amongst scheduled methods, specificity only needed to be assessed for the
scheduled method incorporating all peptide targets in order to confirm individual target
specificity.

(A)

(B)
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(C)

Figure 26. Two component (A), three component (B) and four component (C) mixtures
containing combinations of menstrual blood (MB), peripheral blood (PB), saliva (SA),
vaginal secretions (VS), urine (UR), and semen (SE). Green boxes indicate the presence
of a peptide at a detectible level and red boxes indicate the absence of a peptide at a
detectible level. Bolded boarders indicate where positive results were expected based on
mixture composition.

Prostatic acid phosphatase had multiple peptides that failed to be detected in
samples that contained semen (samples not shown). At the same time, these peptides were
detected in samples that did not contain semen. In all instances where prostatic acid
phosphatase was detected in a mixture that did not contain seminal fluid, vaginal secretions
were present in the mixture. This is consistent with the published literature which indicates
the presence of acid phosphatase in vaginal secretions albeit at lower concentrations than
seminal fluid. Epididymal secretory protein was also identified in two samples containing
semen-free vaginal fluid. Given the lack of observed specificity of these two biomarkers,
all peptides for both prostatic acid phosphatase and epididymal secretory protein were
eliminated from the final seminal fluid assay. The final method, therefore, that was found
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to be most specific for seminal fluid and which had the greatest sensitivity is included in
Appendix III. This method was used for the remainder of the study.
A sensitivity comparison of the monoplex assay to the original multiplex assay for
all six biological fluids demonstrated a gain in sensitivity of nearly one order of magnitude.
The original multiplex was able to detect a pooled sample of seminal fluid at a dilution of
1:16,384 while the optimized monoplex assay for seminal fluid was able to detect seminal
fluid at a dilution of 1:131,072 (Figure 27).
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Figure 27. (A) Sensitivity limits of seminal fluid for the original multiplex assay for six
forensically relevant biological fluids. (B). Sensitivity limits for semen using the optimized
monoplex assay for seminal fluid representing a three-fold increase in sensitivity obtained
for seminal fluid.
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An evaluation was made to determine the total amount of protein can be loaded on
the sample preparation robotic platform (Agilent AssayMAP Bravo) for injection onto the
LC-MS/MS instrument. To achieve this, peak areas for targeted peptides were assessed
for overall abundance. A decrease in peak abundance with an increase in total protein
targeted for digestion indicates C18 cartridge overload on the robotic platform. The C18
cartridges on the robotic platform use a hydrophobic sorbent phase to retain peptide
fragments. As more protein is loaded onto the sorbent phase, preferential binding of
hydrophobic peptides and concurrent loss of hydrophilic peptides will occur. As the more
abundant seminal fluid peptides in the final assay are hydrophilic, this would result in
decreased assay sensitivity. Based on the results of these experiments the optimum protein
loading quantity was determined to be 100 µg based on observations made of all peak areas
for protein targets (Figure 28).

Figure 28. Peptide abundance as measured by average peak area compared to total protein
loading amount on the C18 cartridge. As the peptides for epididymal secretory protein are
the most hydrophilic, they were used to assess when preferential binding on the C18
cartridge occurred.
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4.2.3. Assessment of the Sensitivity of the Monoplex QQQ-MRM Assay for Seminal
Fluid Using Authentic Post-Coital Cervico-Vaginal Samples

The extent to which the optimized monoplex QQQ-MRM assay for semen could
extend the post-coital interval during which the presence of seminal fluid could be reliably
detected in cervico-vaginal samples was assessed. A small cutting from each swab was
collected and placed in 500 µl of Universal Buffer (Independent Forensics). This solution
contains buffer and salts (Tris, NaCl, KCl) for physiological stability, a chelating agent
(EDTA) for stability, detergents and surfactants (Triton X-100 and Tween 20) for
extraction efficiency and solubility maintenance, protein (BSA) for reducing non-specific
adsorption and loss and a preservative (sodium azide). Following a 30-minute incubation
at room temperature with agitation, manufacturer recommended volumes were tested using
ABAcard® p30 (Abacus Diagnositcs), RSID™-Semen (Independent Forensics), and PSA
Semiquant (Seratec). Consistent with the published literature, the ability to generate
positive results for seminal fluid (with one exception) using immunochromatographic
assays were lost at just 48 hours post-coitus (Table 38). Analysis of authentic post-coital
cervico-vaginal swabs using the QQQ-MRM monoplex assay for seminal fluid, however,
was demonstrated to greatly extend the post-coital interval of detection for seminal fluid.
Semen in the same paired samples was detected up to 8 days post-coitus using the QQQMRM assay, not only far exceeding the sensitivity of commercial antibody-based methods
but matching and exceeding that reported for DNA-based approaches (Table 39).
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Table 38. Immunochromatographic Results for Seminal Fluid using the RSID™ Semen
(semenogelin) and the ABAcard® p30 and PSA Semiquant (PSA/p30) Assays Kits.
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Table 39. QQQ-MRM Assay Results for Seminal Fluid Protein Targets PSA/p30 and
Semenogelin I and II.
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4.3 Discussion

For these experiments, a monoplex (single body fluid) QQQ-MRM assay was
developed to enhance the sensitivity of seminal fluid detection beyond that of both the
multiplex method and contemporary immunochromatographic assays. By eliminating from
the multiplex, proteins not specific to seminal fluid and adding additional seminal fluid
proteins that had not previously been used, the resulting monoplex assay maximized
instrument dwell time efficiency and thus detection sensitivity. The sensitivity limit for this
new seminal fluid specific assay was such that a 1 to 131,072 dilution of seminal fluid
could be confidently detected. Application of the optimized assay to two-, three- and fourcomponent mixtures of semen, vaginal and menstrual fluids, saliva, urine, and peripheral
blood showed it to be highly sensitive and specific for human seminal fluid. Analysis of
authentic post-coital cervico-vaginal swabs demonstrated that the enhanced sensitivity of
the QQQ-MRM assay far exceeded that of commercial antibody-based methods as
illustrated by the detection of semen in authentic vaginal swabs collected up to 8 days post
coitus. With a level of sensitivity that is equal to or greater than that of Y-STR DNA
analysis, comes the need to better understand how quantitative levels of semen peptides
might correlate with recoverable male DNA. A “peptide cutoff/threshold level” for
example may aid forensic analysts in assessing the likelihood of obtaining an interpretable
male DNA profile from the remainder of the sample extract. Similarly, such quantitative
thresholds could be used for paired analyses of seminal fluid-free vaginal swabs (i.e.,
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QQQ-MRM vs. immunochromatography) to better estimate the actual rate of false
positives in widely used serological tests.
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CHAPTER 5: QUANTITATIVE SEMINAL FLUID DETECTION BY MASS
SPECTROMETRY AS AN INDICATOR OF MALE DNA PROFILING SUCCESS
AT EXTENDED POST-COITAL INTERVALS
5. Introduction

Despite their prevalence, sexual assault kit (SAK) samples can often be among the
more challenging samples handled by forensic laboratories. Using standard autosomal
short tandem repeat (STR) DNA profiling, an abundance of female DNA on intimate swabs
can mask the presence of trace quantities of male DNA. While this can be overcome by
using male-targeted Y- STR profiling/haplotyping, the statistical weight of a Y-STR match
is typically a tiny fraction of that calculated for an autosomal match. PCR inhibitors from
bacteria, blood, fecal matter and/or other chemical compounds may be present which
impede DNA amplification. Finally, SAK samples encompass wide variation with regard
to the age and quality of the biological material. These factors alone – or in combination –
can make it difficult to generate an informative male DNA profile or haplotype using either
autosomal or Y-STR chemistries. In fact, many SAK samples fail to produce any detectable
male DNA at all [115]. As a result, forensic practitioners have long relied on traditional
serological screening as a means of identifying those samples that are the best candidates
for successful DNA profiling.
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Traditional workflows for the processing of SAK samples have relied upon enzyme
activity and antibody-binding based serological tests for the detection of seminal fluid
and/or saliva as well as microscopy for the detection of spermatozoa. The laborious nature
of performing multiple serological assays to screen evidence and the uncertainty associated
with what are typically presumptive results, however, have contributed to increased
popularity of Y-screen assays as an alternative workflow for SAK samples.
Currently, many forensic laboratories use one of two Y-screen workflows. In the
first approach, all samples undergo differential extraction to enrich for sperm cells followed
by male DNA quantitation to select samples for advancement to genetic profiling. In the
second approach, rapid lysis of a test cutting is followed by male DNA quantitation to
prioritize samples for differential extraction and genetic profiling. While both approaches
achieve rapid screening for the presence of a detectible male contributor, they require that
either laborious differential extraction be used for all samples or multiple cuttings be
extracted/quantified for each item. More critically, though, neither method provides
investigators with any serological information. The resulting lack of critical
investigative/biological context, opens the door to alternative explanations for the presence
of the male DNA (e.g., secondary/indirect transfer of trace DNA from skin cells or cellfree DNA sources [116-118]). In these increasingly common types of cases involving trace
DNA profiles, the ability to detect semen provides both investigators and the trier of fact
with critical context for evaluating what are often the contradictory claims of the victim
and the defendant.
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Traditional serological assays, however, lack comparable sensitivity to that of Yscreen workflows meaning that many SAK samples that yield interpretable DNA profiles
would not likely yield useful serological information even if they were tested. In addition
to the sensitivity limitations associated with degradation, dilution and visual interpretation
of immunochromatographic assays for PSA or Sg I/II, false positive indications of seminal
fluid may also arise due to the presence of the target antigen in biological fluids other than
semen, cross-reactivity or other non-specific antibody binding events. This underscores the
presumptive nature of these assays. The PSA glycoprotein, for example, is a serine
protease [119] secreted by the prostate that cleaves semenogelin [120]. This is responsible
for the liquefaction of seminal fluid. PSA is present in seminal fluid at concentrations that
range from 0.2 to 5.5 mg/mL [85, 121]. While PSA concentrations are highest in seminal
fluid, however, it is also present in vaginal fluid (originating from the periurethral gland
that is homologous to the prostate [14]), albeit at what are typically lower levels [16, 121125]. Saliva, serum, breast milk and amniotic fluid also contain low levels of PSA (Table
40). Based on these reported concentrations, however, only breast milk and amniotic fluid
may contain sufficient PSA concentrations to produce a positive test result using lateral
flow assays designed for seminal fluid detection. Similarly, the Sg I/II proteins originate
mostly from the seminal vesicle and are the main component of semen coagulum [126].
While Sg I/II concentrations are highest in seminal fluid (10 to 20 mg/mL) [126], it too is
not semen specific. Transcripts for Sg I have been found in the gastrointestinal tract
including tissues of the throat and skeletal muscle while transcripts for Sg II have been
found in kidney tissue. Based on the reported concentrations of PSA and Sg in other fluids,
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however, it is unclear as to whether false positive results on lateral flow assays with nontarget body fluids are been due to trace but detectible levels of these proteins or due to nonspecific antibody binding events akin to those demonstrated in Chapter 2 of this
dissertation. Regardless, the need for an enhanced approach to screening SAK samples
which simultaneously provides both a reliable means of selecting/prioritizing samples for
DNA profiling as well as reliable serological information has been demonstrated.

Table 40. PSA Concentrations in Biological Matrices other than Seminal Fluid.

It has already been demonstrated that a QQQ-MRM assay for the detection of
seminal fluid provides enhanced detection sensitivity and accuracy relative to
immunochromatography. This approach (which need not consume cellular DNA) allows
the detection of seminal fluid in authentic vaginal swabs past the reported post-coital
interval for Y-STR DNA typing. Thus, the overarching goal of this research was to glean
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additional practitioner-relevant information through a quantitative analysis of sexual
assault samples collected across a wide post-coital interval.
To achieve this, an already robust qualitative QQQ-MRM assay for seminal fluid
was converted into a quantitative assay. Absolute quantitation was achieved through the
use of intact protein and isotopically labeled synthetic peptide internal standards [127] for
multiple peptides from the same protein [128]. Then, by comparing quantitative protein
data with genetic data from Y-STR testing of the same samples, it was possible to assess
the degree of correlation between the detection of a given quantity of targeted seminal fluid
proteins and the success rates for obtaining a male Y-STR profile. Additional studies
focused on assessing the rate and potential impact of true false positive
immunochromatographic results with casework-type samples. A true false positive result
is defined as a false positive due to non-specific antibody interactions rather than a positive
result arising as a result of target protein expression in a non-target tissue (i.e., the detection
of a seminal fluid biomarker protein expressed in a body fluid other than seminal fluid).
These goals were achieved through the successful completion of the following three core
research objectives:
(1) A quantitative QQQ-MRM assay was developed and optimized using synthetic
PSA and Sg I/II proteins to establish a standard curve which was then used to
quantitate these proteins in forensic-type samples.
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(2) The correlation between peptide quantitative values for target seminal fluid peptides
and the ability to generate Y-STR profiles from vaginal swabs collected at various
post-coital intervals was assessed.
(3) The rate of false positive results associated with immunochromatographic tests of
semen-fee vaginal swabs was determined to assess whether target proteins in the
sample were actually present above the assay’s sensitivity threshold.

5.1 Methods

5.1.1 Development of an Absolute Quantitative QQQ-MRM Assay for Seminal Fluid

Known concentrations of PSA/p30 and Sg were added to vaginal secretions and
digested with trypsin. Synthetic isotope-labeled peptides retain the chemical and
chromatographic properties of natural peptides but have a mass shift due to the introduction
of a stable “heavy” isotope. These “heavy” peptides were added to samples at a fixed
concentration and the ratio of the target peptide recovered from a standard to the synthetic
labeled peptides was plotted against the known concentration to generate a linear standard
curve. The response of a natural peptide in a test sample was normalized to the “heavy”
standard in order to calculate its concentration from the standard curve [129, 130].
Non-matrix curves for each peptide were used to select protein standard and labeled
peptide concentrations for the in-matrix curve. A fit-for-purpose analytical method
assessment was then performed in order to assess the performance of the assay. This
included evaluating the linearity/calibration model, limit of detection (LOD), and limit of
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quantitation (LOQ). A straight fit line using weighted linear regression with inverse
concentration-squared weights was used to evaluate the working range. Acceptable criteria
for these parameters included correlation coefficient >0.98. LOD was assessed using three
blank pooled vaginal matrix samples analyzed over three runs concurrently with fortified
serial dilutions of the lowest standard. The LOD was defined as the lowest concentration
yielding an average signal:noise ratio greater than 3. The precision and accuracy of the LOQ
was evaluated across a three-day reproducibility study from three separate sources of blank
vaginal swabs. An acceptable LOQ level was defined as a %CV within 20% of the
calculated mean and within 20% of the target (0.5 fmol/µl).

5.1.2 Assessment of the Relationship between Quantitative Levels of Target Seminal
Fluid Peptides and the Generation of Y-STR Profiles from Post-Coital Vaginal Swabs

Self-collected vaginal swabs were collected at various post-coital intervals (2 swabs
per sample) from study participants who completed a survey indicating the time since their
last known act of barrier-free sexual intercourse. Fifty (50) self-collected post coital vaginal
samples were tested.
Each self-collected post coital vaginal swab was solubilized in 1mL of deionized
water for 30 minutes at room temperature with periodic vortexing. Swabs were then placed
into spin basket inserts and centrifuged at 1200 RPM for 10 minutes to pellet cellular
material. After centrifugation, the swab cutting and spin baskets were removed. The
supernatant was transferred to a clean 1.5mL microcentrifuge tube and cuttings were placed
back into pelleted material and retained. For the QQQ-MRM analyses, 100 µl of extract
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(i.e., the supernatant) was used. To ensure quantitative concordance, swabs were analyzed
in duplicate by quantitative QQQ-MRM and the values averaged to determine the
concentrations of target seminal fluid proteins.
The pelleted material and cuttings underwent DNA extraction utilizing an
AutoMate Express Robotic Extraction platform (Thermo Fisher Scientific) and the
PrepFiler Express chemistry (Thermo Fisher Scientific). All samples were eluted in a final
volume of 100 µl. All DNA extracts were quantified by Quantifiler® Trio and typed using
Yfiler® Plus chemistries (Thermo Fisher Scientific) on a 3500 Genetic Analyzer. The
resulting data were analyzed with GeneMapper IDX Software. The analytical thresholds
(AT) applied for profile interpretation were based on previous validation studies that
independently evaluated the S/N characteristics for each dye channel. For a 15 second
injection the AT values used were blue: 40 RFU; green: 55 RFU; yellow: 50 RFU; purple:
50 RFU; and red: 50 RFU. Seminal fluid protein content was compared to the percent of
Y-STR loci in order to determine the seminal fluid peptide concentration at which Y-STR
typing consistently failed to yield interpretable results.

5.1.3 Estimation of the Rate of Authentic False Positive Results Associated with
Immunochromatographic Assays for Seminal Fluid
Self-collected vaginal swabs (2 swabs/sample) were collected from ≥50
participants who were not engaging in barrier-free vaginal intercourse and who indicated
that it has been at least 1 month since the last known act of condomless sexual intercourse.
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A matrix blank (pooled vaginal fluid) and positive semen control was analyzed with each
batch of samples.
Each full swab was solubilized in 1mL Universal Buffer (Independent Forensics)
for 30 minutes at room temperature with periodic vortexing. Swabs were then placed into
spin basket inserts and centrifuged at 1200 RPM for 10 minutes to pellet the cellular
material. Following centrifugation, the cutting and baskets were removed and discarded.
The supernatant was transferred to a clean 1.5mL microcentrifuge tube and pelleted
material was retained. The samples were analyzed per the manufacturer’s instructions for
the RSID Semen (Independent Forensics), PSA SemiQuant® (Seratec), and ABAcard p30
(Abacus Diagnostics) immunochromatographic assays; 100 µl extract was placed in the
sample window of the cassette for RSID Semen and 200 µl extract was placed in the sample
window of the cassette for ABACard p30 and PSA SemiQuant®. The remaining
supernatant was prepared for analysis by the QQQ-MRM method.
As the purpose of this objective was to evaluate the rate of true false positive
reactions obtained with the immunochromatographic assays being analyzed, normal testing
procedures that closely followed those recommended by manufacturers were desired. It is
for that reason that swabs were solubilized in Universal Buffer instead of water as per
internal standard operating procedures for QQQ-MRM sample preparation. This required
the addition of an initial solid phase extraction for the 100 µl sample extract prior to
digestion and introduction to the LC system in order to prevent the introduction of
detergents to the LC column.
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Any samples producing positive results on any of the immunochromatographic
assay were evaluated to determine whether the target protein was actually present at levels
above the reported sensitivity limits of the lateral flow tests. If the mass spectrometry
results indicate a target protein concentration below the sensitivity limits, the result will be
considered a false positive event (pelleted material from swabs was also saved to confirm
the absence of sperm cells using Sperm HyLiter). For any samples with positive QQQMRM results (i.e., a target peptide concentration above the LOQ) were analyzed in
duplicate and the values averaged to determine the concentrations of target seminal fluid
proteins and to ensure quantitative concordance between measurements.

5.2 Results

5.2.1 Development of an Absolute Quantitative QQQ-MRM Assay for Seminal Fluid
The ratio of the synthetic isotope-labeled “heavy” vs. the “natural” peptide was
plotted against known peptide concentrations to generate a linear standard curve for
absolute quantitation. Similarly, with any case-type sample tested in a forensic context, the
response of the tryptic “natural” peptide vs. the “heavy” standard can be used to calculate
its concentration from the standard curve.
Initially, neat or non-matrix curves for each peptide were generated in order to
establish an analytic measurement range (AMR) for the analytical assay. Calibrators were
generated in 2% acetonitrile with 0.1% formic acid at the following levels: 0.5 fmol/µL, 1
fmol/µL, 5 fmol/µL, 10 fmol/µL, 25 fmol/µL, 50 fmol/µL, and 100 fmol/µL with the
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isotopically labelled internal standards added at 25 fmol/µL. Linear calibration curves with
a weighting factor of 1/2 were generated for each peptide, producing a correlation
coefficients of 0.99 or greater.
In-matrix curves (i.e., in vaginal fluid) were then assessed to ensure the reliability
of the analytical method. This performance check assessed the calibration model, LOD,
and LOQ over the course of three days to verify reproducibility and performance.
The calibration model was assessed from three separate calibration curves
generated over three separate days. The intercept and linearity/R2 were assessed for each
peptide within the scope of the analytical method. All compounds performed adequately
with R2 values of >0.99 across all test batches (Table 41 and Figure 29).

Table 41. Assessment of the Analytical Calibration Model.
Calibration Model Assessment
Compound

R2

Semenogelin QITIPSQEQEHSQK

0.99 0.00

Semenogelin GSISIQTEEQIHGK

0.99 0.01

PSA LSEPAELTDAVK

0.99 0.00
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Intercept

Figure 29. Linear calibration models for all peptides within the scope of the analytical
method.

The LOQ was assessed by analyzing three separate sources of blank matrices in
triplicate over three days. Each of these values was quantified against a calibration curve
prepared on that same day in order to determine the method bias and precision. Method
bias, which was measured as the % difference from the target concentration (0.5 fmol/ µL),
was below 15% for all target analytes. Similarly, precision variation was below 15%
showing acceptable LOQ reproducibility (Table 42). Representative chromatograms for
each target are shown in Figure 30. The final quantitative QQQ-MRM seminal fluid assay
method parameters are detailed in Appendix III.
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Table 42: Limit of quantitation assessment
Limit of Quantitation Assessment
Compound

Bias (% Difference)

Precision (%CV)

Semenogelin QITIPSQEQEHSQK

12.9

7.7

Semenogelin GSISIQTEEQIHGK

3.0

4.7

PSA LSEPAELTDAVK

1.3

14.7

Figure 30. Chromatogram for each target analyte at the limit of detection and
quantitation.

5.2.2 Assessment of the Relationship between Quantitative Levels of Target Seminal
Fluid Peptides and the Generation of Y-STR Profiles from Post-Coital Vaginal Swabs

Seminal fluid protein concentrations were compared to the percent of Y-STR loci
detected (out of a total of 27 loci) to determine whether there was a consistent relationship
between seminal fluid peptide concentrations and Y-STR haplotyping success (Table 43).
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Out of the 50 samples analyzed, there was full concordance in all but 2 instances between
the QQQ-MRM target peptide concentrations and the ability to produce interpretable YSTR profiles when targeting the semenogelin I peptide target (QITI peptide). The PSA/p30
peptide target (LSEP peptide) did not perform as well as the semenogelin peptide targets.
In these two instances (samples number 22 and 25) partial DNA profiles were produced
with 67% and 52% of donor alleles detected above the applied analytical thresholds
respectively. In these two samples however, no target seminal fluid peptides were detected.
In all other instances, when no Y-STR donor alleles were detected, no target peptides were
detected either. Conversely, when full and partial Y-STR profiles were produced the QITI
peptide was detected above the LOQ and could be reliably quantified. In three instances,
Y-STR profiles were obtained within a defined “uninformative range” (between 2 to 5
alleles produced).

In these three instances, mixed results were obtained for both

semenogelin targets. In two instances both the QITI and GSIS peptides were detected
above the LOQ and in 1 instance they were not detected.
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Table 43. Relationship Between Target Protein Quantity and Y-STR Profiling Success in
Post-Coital Vaginal Swabs.
Sample ID
1

Days
Post
Coitus
1

2

1

3

1

4

1

5

1

6

1

7

1

8

1

9

1

10

1

11

1

12

2

13

2

14

Unknown

15

2

16

3

17

3

18

3

19

3

20

2

21

3

22

2

23

3

24

3

25

2

26

3

27

4

28

5

29

2

30

4

31

4

32

4

33

7

34

7

35

3

36

3

37

3

38

4

39

4

40

4

41

4

42

4

43

4

44

5

45

5

46

5

47

6

48

6

49

8

50

8

Y Filer Plus (15s)

%Y
Profile

Full (26 alleles)
Full (26 alleles)
Full (27 alleles)
Full (27 alleles)
Full (27 alleles)
Full (27 alleles)
Full (27 alleles)
Full (27 alleles)
Full (27 alleles)
Full (26 alleles)
Full (26 alleles)
Full (27 alleles)
Full (27 alleles)
Full (26 alleles)
Full (27 alleles)
Full (27 alleles)
Full (27 alleles)
Full (26 alleles)
Full (26 alleles)
Partial (22 alleles)
Partial (19 alleles)
Partial (18 alleles)
Partial (17 alleles)
Partial (17 alleles)
Partial (14 alleles)
Partial (6 alleles)
Partial (5 alleles)
Partial (4 alleles)
Partial (2 alleles)
1 Allele Detected
1 Allele Detected
1 Allele Detected
1 Allele Detected
1 Allele Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected
No Alleles Detected

100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
81
70
67
63
63
52
22
18
15
8
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

QITI Protein GSIS Protein LSEP Protein
Concentration Concentration Concentration
(fmol/ul)
(fmol/ul)
(fmol/ul)

11.257
3.582
25.8335
33.0449
424.9819
1416.9186
1.4199
2.4021
11.7173
1.0639
0.8404
1.0763
132.1065
1.587
88.8538
8.5282
5.2404
1.9207
1.399
0.9687
0.854
(-)
1.0265
0.9473
(-)
1.098
1.5929
(-)
0.5471
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)

1.67
0.6244
9.7626
10.617
35.5791
199.8537
0.9801
1.8503
7.525
0.8321
0.7073
0.8259
36.4736
0.8126
19.1607
4.5612
2.8667
(-)
(-)
0.8106
1.5641
(-)
0.9836
0.7499
(-)
2.8809
1.4179
(-)
0.5202
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)

(-)
(-)
(-)
(-)
0.9348
2.2256
0.6485
1.4456
5.0878
1.6974
1.4372
0.5832
(-)
(-)
(-)
(-)
(-)
(-)
(-)
0.6412
(-)
(-)
0.7347
0.5549
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)

Note: Days post coitus was self-reported in the sample questionnaire that accompanied
collection packets. Percent Y-STR Profile was calculated by dividing the number of
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observed donor alleles detected by the number of donor alleles expected. Green boxes
indicate a positive result (for YSTR results, this is represented by the detection of 6 or more
donor alleles; for the QQQ-MRM results, this is represented by the quantitative value of a
target peptide). Red boxes indicate the absence of a peptide at a detectible level on the
QQQ-MRM method and 1 or fewer donor alleles detected. Yellow boxes denote partial
Y-STR profiles falling within the uninformative range of 2 to 5 donor alleles detected.

5.2.3 Estimation of the Rate of Authentic False Positive Results Associated with
Immunochromatographic Assays for Seminal Fluid

Originally, this research proposed to analyze 50 negative vaginal swabs, however,
in order to confirm these findings, an additional batch of 50 negative vaginal swabs (for a
total of 100 samples) was tested. Out of the 100 samples analyzed, 17 produced false
positive results for ABAcard p30 and PSA Semiquant while 6 produced false positive
results for RSID Semen resulting in a 17% and 6% false positive rate respectively.
Interestingly, in no instance, did a sample produce a false positive result on all three
immunochromatographic assays. It was also not always the case that a sample which
produced a false positive on one assay targeting PSA (ABAcard p30 or PSA Semiquant)
would necessarily produce a false positive result on the other assay targeting PSA.
Subsequent analyses of these presumed false positive samples by mass
spectrometry did not detect the presence of the protein targets for any of the
immunochromatographic assays that were evaluated. This renders more probable the
inference that prostate specific antigen and semenogelin proteins were either not present in
these samples or were present at such low levels that one would not expect to detect them
by immunochromatography (Tables 44-45; Figure 31).
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Additionally, all cellular components of the 26 samples that produced positive
immunochromatographic results were confirmed to be sperm free utilizing Sperm HyLiter
and fluorescent microscopy. This, coupled with the quantitative QQQ-MRM results
indicates that the positive immunochromatographic results were likely to be true false
positive non-specific binding events rather than an unexpected positive result due to the
presence of the target proteins at low levels in these particular samples. These data
underscore the presumptive nature of immunochromatographic assay results and should
alert forensic practitioners to the fact that the rate of true false positive results is not
insubstantial.

138

Table 44. Batch 1 of “seminal fluid free” vaginal swabs.

Note: Green boxes indicate a positive test result (for the immunochromatographic assays
means a line both at the control and the test zones; for the QQQ-MRM assay, this means a
target peptide quantity above the LOQ). Red boxes indicate the absence of a peptide at a
detectible level on the QQQ-MRM assay and a negative test result on the
immunochromatographic assays. Gray boxes indicate the sample was not tested.
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Table 45. Batch 2 of “seminal fluid free” vaginal swabs.

Note: Green boxes indicate a positive test result (for the immunochromatographic assays
means a line both at the control and the test zones; for the QQQ-MRM assay, this means a
target peptide quantity above the LOQ). Red boxes indicate the absence of a peptide at a
detectible level on the QQQ-MRM assay and a negative test result on the
immunochromatographic assays. Gray boxes indicate the sample was not tested
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Figure 31. Sample images of false positive results obtained following testing of semenfree vaginal swabs using multiple commercial immunochromatographic assays designed
to target PSA (Seratec Semiquant and ABAcard) or Sg (RSID Semen) in seminal fluid
illustrating the range of strong to weak false positive results obtained.
5.3 Discussion

The data outlined in this chapter illustrate how the use of high-sensitivity targetedion mass spectrometry can be used to not only address the limitations of existing methods
for semen detection but also to establish a framework for the use of quantitative
information on seminal fluid proteins in forensic testing. This will aid the development of
more informed confirmatory interpretation guidelines for protein-based seminal fluid
identification; inform forensic analysts about the probability of successful downstream
genetic analysis; and address the inherent limitations of the serological approaches
currently employed in case-working laboratories to detect the potential presence of seminal
fluid in sexual assault-type evidentiary samples. In toto, this assay will provide the forensic
community with powerful information to aid in the investigation of sexual assault.
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5.4. Future Directions and Impact on the Criminal Justice System

Past work comparing the proteomes of five body fluids commonly encountered in
a case-working context resulted in the identification of multiple candidate high-specificity
biomarkers for the confident identification of human body fluids. The current studies have
further expanded this body of knowledge. A triple Quadrupole Multiple Reaction
Monitoring (QQQ-MRM) assay for the simultaneous confirmatory detection of protein
biomarkers in six human body fluids was produced and developmentally validated. This
multiplex QQQ-MRM assay will provide analysts with high confidence in the body fluid
identification results obtained for a given stain. This is made possible by the use of not just
one protein biomarker but rather on the presence of multiple proteins which in turn are
based on multiple precursor and product ion pairs. Studies on casework-type samples have
demonstrated the reliable performance of the assay; even with aged/weathered or otherwise
chemically compromised samples. It was further demonstrated that the validated assay has
the ability to overcome the inherent limitations of the antibody-based tests currently
employed by case-working laboratories for the detection of seminal fluid.
A seminal fluid specific monoplex assay was then developed specifically for the
analysis of sexual assault samples with the goal of further enhancing the overall sensitivity
for detecting trace levels of semen-specific target protein biomarkers. The use of a
monoplex QQQ-MRM assay that has been optimized for sensitivity and which can detect
partially degraded seminal fluid markers will enhance the ability of forensic analysts to
unambiguously detect semen in two significant ways. First, this approach will enable
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analysts to report the confirmatory identification of semen in post-coital samples collected
as much as 8 days after intercourse. Second, this approach may allow for the confirmation
of seminal fluid in samples where there may be insufficient DNA to obtain an interpretable
profile (e.g., in cases of vasectomy, lack of ejaculation or minimal sexual contact). In short,
this will make it possible to obtain probative results from samples that might otherwise
have yielded inconclusive or no results at all. This will provide the forensic and criminal
justice communities in the United States and internationally with a powerful tool to aid the
investigation and prosecution of sexual assault.
The functionality of the monoplex method was then enhanced, to enable the
absolute quantitation of targeted high-specificity seminal fluid protein biomarkers in the
panel. A major positive impact of now having a quantitative monoplex QQQ-MRM assay
optimized for sensitivity is that it has enhanced the ability of forensic analysts to
confidently detect seminal fluid well beyond the typical 1- to 2-day post-coital interval. By
obtaining precise measurements of targeted protein levels and correlating these with the
likelihood of successful DNA typing, practitioners will be able to leverage quantitative
data on seminal fluid proteins in their decision making on downstream analyses for sexual
assault swabs. This will enable practitioners to better identify for forensic investigators
those items of evidence that are most likely to produce potentially probative results. It will
also facilitate the more efficient allocation of resources by allowing analysts to focus their
downstream genetic analyses efforts on those samples where protein quantitation results
are predictive of successful male DNA typing. This will also have the effect of reducing
the frequency with which analyst are asked to explain in a court of law the apparent
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discrepancy between having an intimate sample that yields an interpretable male profile
but for which serological testing was either not performed or failed to indicate the presence
of seminal fluid.
Future work should evaluate a fully-automated immunoaffinity Multiple Reaction
Monitoring mass spectrometry (iMRM) method for the analysis of SAK samples. The
iMRM workflow uses custom antibodies to specifically enrich for targeted tryptic peptides.
This would produce a highly purified final extract for analysis by LC-MSMS to reliably
screen for both seminal fluid and saliva in SAK evidence. In a proposal submitted to the
US Armed Forces, the use of this iMRM proteomics strategy has been proposed to set
statistically supported criteria for prioritizing SAK samples for genetic analysis based on
preliminary data detailed in Chapter 5.

Both peptide and male-DNA quantitation

thresholds would be established for predicting DNA typing success. Using a separate
dataset, type I and II error rates would be compared for the overall iMRM workflow to
existing Y-screen strategies for SAK sample assessment using post-coital samples. Frontend sample solubilization and fractionation procedures can also be optimized. The soak
and spin methods employed in this research can be compared to new commercial products
(Qiagen AllPrep) designed to fractionate DNA, RNA and protein to determine which
methods produces the greatest chance of recovery for both protein and genetic material.
Finally, a blind side-by-side assessment of novel serological workflows and strategies
including proteomics, epigenetics and RNA-based techniques would provide the forensic
community with a more informative look at the progress being made in each of these areas
of research as compared to currently employed testing methodologies.
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APPENDIX II: CRITICAL VALUES FOLLOWING POST-HOC TUKEY TEST
COMPARING UNSCHEDULED (METHOD 1) AND SCHEDULED (METHODS
2-6) ITERATIONS OF A SEMINAL FLUID MONOPLEX ASSAY FOR ALL
TARGET PEPTIDES
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Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

DIFS

Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

LSEP

Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

ELSE

P < 0.05

P > 0.05

Method 1
0
0.075
0.069
0.066
0.058
0.066

df=12

Method 1
0
0.080
0.074
0.077
0.077

df=10

P > 0.05

P > 0.05

0
3.20E-03
2.96E-03
0
2.43E-04
0
0

0
5.80E-03
8.47E-03
0.016
9.28E-03
0
2.67E-03
0.011
3.48E-03

0
7.97E-03
8.11E-04

0
7.16E-03

0

Method 2 Method 3 Method 4 Method 5 Method 6

P < 0.05

0
6.30E-03
3.10E-03
3.34E-03

Method 2 Method 3 Method 4 Method 5 Method 6

P < 0.05

Method 1 Method 2 Method 3 Method 4 Method 5 Method 6
0
0.113
0
0.116
2.54E-03
0

df=6

Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

DIFT

Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

DVSQ

Method 1
Method 2
Method 3
Method 4
Method 5
Method 6

LPSE

P < 0.05

P > 0.05

P < 0.05

P > 0.05

P < 0.05

P > 0.05
Method 1 Method 2 Method 3 Method 4 Method 5 Method 6
0
0.045
0
0.043 1.68E-03
0
0.043 1.70E-03 2.14E-05
0
0
0

df=8

Method 1 Method 2 Method 3 Method 4 Method 5 Method 6
0
0.027
0
0.025 2.51E-03
0
0.022 5.46E-03 2.95E-03
0
0.026 1.71E-03 7.92E-04 3.74E-03
0
0.031 3.03E-03 5.54E-03 8.50E-03 4.75E-03
0

df=12

Method 1 Method 2 Method 3 Method 4 Method 5 Method 6
0
0.045
0
0.047 1.70E-03
0
0.078
0.033
0.031
0
0
0

df=8
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